Safe Pro Group (NASDAQ: SPAI) has released its “Innovation Day Technology Illustration Teaser” video, showcasing the company’s AI-powered ecosystem of computer vision software and mapping tools for drone-based threat detection. The video demonstrates how Safe Pro’s patented “SpotD” technology leverages AI and machine learning trained on one of the world’s largest real-world drone imagery datasets to rapidly detect and map more than 150 types of explosive threats and other objects of interest, including landmines, unexploded ordnance (“UXO”), cluster munitions and ambush drones, while supporting a broad range of aerial and ground-based defense missions through enhanced situational awareness and autonomous threat mapping.
Safe Pro Group Inc. is a mission-driven technology company delivering AI-enabled security and defense solutions. Through cutting-edge platforms like SPOTD, Safe Pro provides advanced situational awareness tools for defense, humanitarian, and homeland security applications globally. The Company is a leading provider of artificial intelligence (AI) solutions specializing in drone imagery processing, leveraging commercially available off-the-shelf drones with its proprietary machine learning and computer vision technology to enable rapid identification of explosive threats, providing a safer and more efficient alternative to traditional human-based analysis methods. Built on a cloud-based ecosystem and powered by Amazon Web Services (AWS), Safe Pro Group’s scalable platform targets multiple markets, including commercial, government, law enforcement, and humanitarian sectors where its Safe Pro AI software, Safe-Pro USA protective gear, and Airborne Response drone-based services can work in synergy to deliver safety and operational efficiency.
NOTE TO INVESTORS: The latest news and updates relating to SPAI are available in the company’s newsroom at http://nnw.fm/SPAI
About NetworkNewsWire
NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer
Greenland Mines (NASDAQ: GRML) announced that Innovation, Science and Economic Development Canada has granted a patent covering technology exclusively licensed by the company for Klotho-based gene therapies targeting cognition, memory and neurodegenerative diseases. The patent protects the use of the secreted Klotho (“s-KL”) RNA splice variant in genetic therapies and includes 42 claims covering its synthesis, delivery methods and potential application across multiple neurological disorders, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis.
The company said the Canadian patent expands its intellectual property portfolio for Klotho-based therapeutics and complements previously issued patents in the United States, China and Europe. Greenland Mines added that process development and manufacturing for lead candidate KLTO-101 is scheduled to begin in August 2026, while KLTO-202 has advanced to GMP manufacturing as the company prepares for regulatory interactions later this year.
Greenland Mines Ltd. is a Nasdaq-listed company with two operating divisions: (1) Mining, focused on the exploration and development of the Skaergaard Project in southeast Greenland and, subject to closing of the previously announced transaction, the Sarfartoq neodymium-praseodymium (Nd-Pr) rare earths project in southwest Greenland; and (2) Biotech, including Klotho’s KLTO‑202 primary indication for ALS. The Company’s strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to GRML are available in the company’s newsroom at https://ibn.fm/GRML
This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on advancing innovative therapies and technologies, was featured in a recent episode of the BioMedWire Podcast. During the program, Executive Co-Chairman and Co-Founder Anthony Durkacz discussed the company’s strategy for advancing Lucid-MS, its lead drug candidate for multiple sclerosis, as well as the commercial opportunity surrounding its unbuzzd product. Durkacz highlighted Lucid-MS’s goal of addressing mobility damage associated with MS and noted that the company has filed an investigational new drug application for a Phase 2 clinical trial, which could represent the candidate’s first administration to human MS patients. He also discussed unbuzzd, a commercially available product designed to accelerate alcohol metabolism, underscoring Quantum BioPharma’s strategy of combining clinical-stage pharmaceutical development with commercial opportunities across neurodegenerative, metabolic and alcohol-misuse conditions.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd and spun out its OTC version to a company, Unbuzzd Wellness Inc. (“UWI”), led by industry veterans. Quantum BioPharma retains ownership of 19.84% (as of March 31, 2026) of UWI at www.unbuzzd.com. The agreement with UWI also includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar product or alternative formulations specifically for pharmaceutical and medical uses.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM
Datavault AI (NASDAQ: DVLT) announced progress on its NIL debit card capability through its embedded banking and payments arrangement with Fiserv while appointing Ronald M. Goldstein to lead professional sports licensing for its NIL Vault (“NILv”) platform. The company said the planned payment wallets and debit cards are intended to enable participating athletes to receive, manage and access funds earned through sponsorship and NIL activities.
Datavault AI said Goldstein, who has more than 35 years of experience in sports marketing, licensing, intellectual property and commercial partnerships, has already begun advancing official licensing initiatives for NIL Vault, including programs involving Josh Gibson, Roberto Clemente and Yogi Berra. The company said the appointments and expanded payment capabilities support the continued development of its planned NIL exchange platform.
Datavault AI(TM) is leading the way in AI-driven data experiences, valuation and monetization of assets in the Web 3.0 environment. The company’s cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic Sciences and Data Sciences divisions.
Datavault AI’s Acoustic Sciences division features WiSA(R), ADIO(R) and Sumerian(R) patented technologies and industry-first foundational spatial and multichannel wireless, high-definition sound transmission technologies with intellectual property covering audio timing, synchronization and multi-channel interference cancellation. The Data Science division leverages the power of Web 3.0 and high-performance computing to provide solutions for experiential data perception, valuation and secure monetization.
Datavault AI’s platform serves multiple industries, including high-performance computing software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy and more. The Information Data Exchange(R) enables Digital Twins and the licensing of name, image and likeness by securely attaching physical real-world objects to immutable metadata, fostering responsible AI with integrity. The company’s technology suite is fully customizable and offers AI- and machine-learning-based automation, third-party integration, detailed analytics and data, marketing automation and advertising monitoring.
The company is headquartered in Philadelphia, PA. Learn more about Datavault AI at https://dvlt.ai.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to DVLT are available in the company’s newsroom at https://ibn.fm/DVLT
Pressure on agencies to adopt response-to-resistance alternatives has intensified, widening demand for tools that can control situations without injury or pain rather than provoke confrontations.
Wrap has built its business around a Non-Lethal Response(TM) platform that converges remote restraint, training, and evidence management, spanning the BolaWrap(R) 150, Wrap Reality(TM), Wrap Vision(TM), Wrap Tactics(TM), and counter-drone solutions.
With the July 2026 launch of WrapShield(TM) and an exclusive U.S. and NATO license to Frenel Imaging’s TPiCore(R) thermal-polarimetric sensing, Wrap is adding an AI-enabled detection layer, beginning with counter-UAS.
A Widening Market for Response-to-Resistance Technology
High-profile use-of-force incidents have driven costly litigation, strained community trust, and increased scrutiny of how officers are equipped and trained. That environment has pushed agencies toward tools that create time, distance, and tactical advantage, particularly in encounters involving individuals in mental- or behavioral-health crises and has widened the customer base beyond traditional policing into corrections, campus safety, healthcare, and transportation security. Wrap Technologies (NASDAQ: WRAP) built its business around closing the response-to-resistance gap with technology that reduces injury to everyone involved.
The company describes itself as a global public safety technology provider developing policing solutions for law enforcement and security personnel across the United States, Europe, the Middle East, Africa and Asia Pacific. Its flagship BolaWrap(R) 150 Remote Restraint Device, along with a growing portfolio of training and evidence-management tools, is designed to give…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to WRAP are available in the company’s newsroom at https://ibn.fm/WRAP
VERAXA Biotech (NASDAQ: VRXA) announced that shareholders overwhelmingly approved all proposals presented at its Extraordinary General Meeting, with more than 99.94% of votes cast in favor and 72.20% of the company’s outstanding share capital represented. The approved measures include the introduction of conditional share capital for shareholder options and warrants, implementation of a capital band through Dec. 31, 2030 and an increase in the maximum size of the board of directors from five to seven members.
The company said the enhanced corporate and financing framework is intended to support its long-term growth strategy by providing greater flexibility for potential acquisitions, strategic collaborations, investment projects, capital markets activities and continued development of its BiTAC(R) technology platform and oncology pipeline. Management said the vote reflects strong shareholder support for VERAXA’s strategy of advancing antibody-based cancer therapeutics while pursuing long-term value creation.
At VERAXA, we are building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, we are rapidly advancing our pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.
BiTAC(R) is a registered trademark of VERAXA Biotech GmbH.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA
Safe Pro Group (NASDAQ: SPAI) announced preliminary, unaudited results indicating second-quarter 2026 revenue is expected to exceed $1.3 million, representing year-over-year growth of more than 1,300% from approximately $92,753 in the second quarter of 2025. The company said the increase was driven by multiple U.S. Army subcontract awards for its AI-powered threat detection and mapping software, with additional momentum supported by expanding relationships with defense prime contractors and the deployment of its technology across both drone and autonomous ground vehicle platforms.
Safe Pro said it continues to broaden its government business pipeline through participation in U.S. Army technology evaluation programs while pursuing additional opportunities with other defense customers, including the U.S. Air Force, as well as post-conflict reconstruction initiatives. The company also highlighted a strong balance sheet with no long-term debt and confirmed it completed its board-authorized stock repurchase program during the quarter, buying 637,084 shares in the open market.
Safe Pro Group Inc. is a mission-driven technology company delivering AI-enabled security and defense solutions. Through cutting-edge platforms like SPOTD, Safe Pro provides advanced situational awareness tools for defense, humanitarian, and homeland security applications globally. The Company is a leading provider of artificial intelligence (AI) solutions specializing in drone imagery processing, leveraging commercially available off-the-shelf drones with its proprietary machine learning and computer vision technology to enable rapid identification of explosive threats, providing a safer and more efficient alternative to traditional human-based analysis methods. Built on a cloud-based ecosystem and powered by Amazon Web Services (AWS), Safe Pro Group’s scalable platform targets multiple markets, including commercial, government, law enforcement, and humanitarian sectors where its Safe Pro AI software, Safe-Pro USA protective gear, and Airborne Response drone-based services can work in synergy to deliver safety and operational efficiency.
For more information on Safe Pro Group Inc., please visit https://safeprogroup.com.
NOTE TO INVESTORS: The latest news and updates relating to SPAI are available in the company’s newsroom at http://ibn.fm/SPAI
About MissionIR
MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.
MIR is where breaking news, insightful content and actionable information converge.
Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer
Datavault AI (NASDAQ: DVLT) announced that former Major League Baseball star Darryl Strawberry has signed as a brand ambassador for Datavault NIL Vault (“NILv”), the company’s upcoming name, image and likeness (“NIL”) exchange platform. Under a services agreement, Strawberry will create promotional content, participate in marketing initiatives and share in revenue generated through his content, while Datavault AI will provide platform support, activity tracking and revenue attribution.
The company said NIL Vault is designed to enable athletes and other public figures to measure, monetize and retain an ongoing interest in the value generated by their name, image and likeness. Strawberry joins the platform ahead of its commercial launch as Datavault AI continues expanding its portfolio of specialized data exchange platforms and expects to announce additional ambassador and content agreements.
Datavault AI(TM) is leading the way in AI-driven data experiences, valuation and monetization of assets in the Web 3.0 environment. The Company’s cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic Sciences and Data Sciences divisions.
Datavault AI’s Acoustic Sciences division features WiSA(R), ADIO(R) and Sumerian(R) patented technologies and industry-first foundational spatial and multichannel wireless, high-definition sound transmission technologies with intellectual property covering audio timing, synchronization and multi-channel interference cancellation. The Data Science division leverages the power of Web 3.0 and high-performance computing to provide solutions for experiential data perception, valuation and secure monetization.
Datavault AI’s platform serves multiple industries, including high-performance computing software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy and more. The Information Data Exchange(R) enables Digital Twins and the licensing of name, image and likeness by securely attaching physical real-world objects to immutable metadata, fostering responsible AI with integrity. The Company’s technology suite is fully customizable and offers AI- and machine-learning-based automation, third-party integration, detailed analytics and data, marketing automation and advertising monitoring.
The Company is headquartered in Philadelphia, PA. Learn more about Datavault AI at https://dvlt.ai.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to DVLT are available in the company’s newsroom at https://ibn.fm/DVLT
VERAXA Biotech (NASDAQ: VRXA) announced the advancement of its bispecific antibody-drug conjugate (“bsADC”) program, VXA-222, after reaching a key technical milestone in its collaboration with OmniAb (NASDAQ: OABI). The company said OmniAb has successfully completed its discovery work, allowing the program to move into its next phase. VXA-222 is designed to target two tumor antigens with a single molecule using an “AND-gate” approach intended to improve precision in treating solid tumors.
Under the collaboration launched in May 2025, OmniAb provided antibody discovery technologies, including its OmniClic(TM) platform, while VERAXA is applying its proprietary linker technology and conjugation expertise to develop and validate the lead bsADC candidate. VERAXA holds exclusive rights to develop and commercialize products arising from the collaboration, with OmniAb entitled to a share of specified revenue generated from resulting products.
At VERAXA, we are building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, we are rapidly advancing our pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.
BiTAC(R) is a registered trademark of VERAXA Biotech GmbH.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA
The combination of a structurally concentrated supply base, rising geopolitical risk from the dominant Russian supplier, and persistent demand from the automotive sector creates a clear rationale for Western nations to secure alternative sources of palladium.
The latest news from Greenland Mines confirms that its Skaergaard project just became more valuable.
The 2026 field season is already underway at Skaergaard, with drilling, bulk sampling for metallurgical test work, geotechnical measurements, engineering studies and environmental baseline all in progress.
Palladium is one of the most strategically important metals on earth, and the supply chain that delivers it to Western manufacturers has never been more exposed. Into that gap steps Greenland Mines (NASDAQ: GRML), which just reported a 31% increase in its indicated palladium equivalent resource at its Skaergaard project in southeast Greenland, one of the largest undeveloped palladium, gold and platinum deposits in the western world.
Most people encounter palladium without knowing it. It sits inside the catalytic converter of nearly every gasoline-powered vehicle on the road, where it converts harmful exhaust gases into less toxic emissions. Automotive applications account for roughly 80% to 85% of total global palladium demand. That makes palladium’s supply chain a direct input into the…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to GRML are available in the company’s newsroom at https://ibn.fm/GRML
Regentis is targeting an estimated $3 billion U.S. cartilage repair market opportunity, supported by approximately 470,000 annual knee cartilage repair procedures and growing demand for regenerative medicine solutions.
Regentis is advancing GelrinC, a potentially first-in-class, off-the-shelf cartilage regeneration platform designed to simplify treatment, improving patient outcomes while fitting current surgical workflows and supporting durable cartilage repair.
These developments underscore the company’s broader mission: To establish a new standard of care in cartilage repair through biomaterial-based regenerative technologies.
Regentis Biomaterials (NYSE American: RGNT) is developing regenerative biomaterial technology as healthcare shifts toward therapies designed to restore damaged tissue rather than simply manage symptoms. With cartilage defects affecting hundreds of thousands of patients each year and contributing to pain, reduced mobility, and degenerative joint disease, the company is targeting one of orthopedic medicine’s largest unmet needs.
GelrinC’s commercial potential is rooted in the combination of clinical differentiation and practical adoption. The product is designed to deliver advanced cartilage repair through a practical, approximately 10-minute, single-step procedure, without cell harvesting, laboratory expansion, patient-specific manufacturing, or a second surgery. At the same time, clinical data generated…
This content has been disseminated on behalf of Regentis Biomaterials Ltd. (NYSE American: RGNT) as part of a paid investor awareness and marketing engagement.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to RGNT are available in the company’s newsroom at https://ibn.fm/RGNT
Wrap Technologies treats non-lethal response as a system rather than a single device, integrating tools, training, and policy into one Non-Lethal Response(TM) ecosystem for modern public safety.
Its platform pairs the patented BolaWrap(R) 150 remote response-to-resistance device with Wrap Reality(TM) VR training, Wrap Vision(TM) evidence management, and Wrap Tactics(TM) digital training, reinforced by IADLEST-certified instruction and human-centered policy frameworks.
In July 2026 the company launched WrapShield(TM), extending that integrated approach from the officer’s belt to an autonomous, AI-enabled platform designed to detect, orchestrate, and respond.
A System, not a Single Device
Law enforcement officers routinely face non-compliant individuals and people in crisis in the narrow interval where verbal commands have not worked but higher levels of force are not yet warranted. Wrap Technologies (NASDAQ: WRAP) builds technology to give officers additional options in that interval, guided by a mission the company describes as helping to save lives through safer outcomes. Rather than selling a standalone tool, Wrap integrates equipment, training, and policy into a single Non-Lethal Response(TM) system so agencies can adopt response-to-resistance capabilities as a complete program.
The company’s solutions have gained meaningful traction, with more than 1,000 law enforcement agencies across 60+ countries deploying Wrap’s technology. Demonstrations continue to expand internationally, including a recent event in Italy, where…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to WRAP are available in the company’s newsroom at https://ibn.fm/WRAP
Datavault AI (NASDAQ: DVLT) announced the appointment of Frank Deo as chief technology officer of its Acoustic Sciences Division, which develops the company ADIO(R), WiSA(R), Event Citadel(TM) and API Media technologies for spatial audio, data-over-sound signaling and live-event systems. Deo previously served as vice president of new media technology at API Media, where he led product engineering for the ADIO platform. He has more than 30 years of experience building media, data and platform technologies, is a Technical Emmy Award winner and is an inventor on 31 issued U.S. and international patents.
Deo will lead efforts to unify the division engineering stack across acquired operations, expand the use of artificial intelligence-assisted development tools, standardize engineering processes and simplify the underlying architecture to reduce operating costs as the business scales. The appointment expands the leadership of the Acoustic Sciences Division as Datavault AI evaluates a potential dividend spinout into a stand-alone public company. The proposed transaction remains subject to board approval, a definitive agreement, closing conditions and any required regulatory approvals.
Datavault AI(TM) is leading the way in AI-driven data experiences, valuation and monetization of assets in the Web 3.0 environment. The company’s cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic Sciences and Data Sciences divisions.
Datavault AI’s Acoustic Sciences division features WiSA(R), ADIO(R) and Sumerian(R) patented technologies and industry-first foundational spatial and multichannel wireless, high-definition sound transmission technologies with intellectual property covering audio timing, synchronization and multi-channel interference cancellation. The Data Science division leverages the power of Web 3.0 and high-performance computing to provide solutions for experiential data perception, valuation and secure monetization.
Datavault AI’s platform serves multiple industries, including high-performance computing software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy and more. The Information Data Exchange(R) enables Digital Twins and the licensing of name, image and likeness by securely attaching physical real-world objects to immutable metadata, fostering responsible AI with integrity. The company’s technology suite is fully customizable and offers AI- and machine-learning-based automation, third-party integration, detailed analytics and data, marketing automation and advertising monitoring.
The company is headquartered in Philadelphia, PA. Learn more about Datavault AI at https://dvlt.ai.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to DVLT are available in the company’s newsroom at https://ibn.fm/DVLT
SS Innovations will showcase its SSi Mantra surgical robotic system at the Society of Robotic Surgery (“SRS”) 2026 Annual Meeting in Florida on July 23-26.
The presentation will feature a live kidney telesurgery broadcast from India, demonstrating the remote capabilities of the SSi Mantra platform.
Chairman and CEO Dr. Sudhir Srivastava to participate in multiple conference presentations covering telesurgery, robotic surgery adoption and regulatory developments.
As of July 6, 2026, more than 12,375 procedures have been completed using the SSi Mantra system, including cardiac, pediatric and telesurgical procedures.
Approximately 2,100 physicians have already been trained on the platform, which has been used across more than 170 different surgical procedures.
SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies, will bring its SSi Mantra surgical robotic system to one of the largest annual gatherings of robotic surgery specialists, highlighting the company’s expanding clinical experience and growing focus on remote surgical capabilities. The company announced that the SSi Mantra will be showcased during the Society of Robotic Surgery (“SRS”) 2026 Annual Meeting, scheduled for July 23-26 in Hollywood, Florida (https://ibn.fm/FkgsY).
The robotic platform will be demonstrated throughout the conference and featured in multiple technical sessions. One of the event’s focal points will be a live robotic telesurgery in which a partial nephrectomy will be performed remotely by…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII
VERAXA Biotech (NASDAQ: VRXA) announced the appointment of Christoph Erkel, Ph.D., as chief scientific officer, effective immediately. Erkel, previously vice president of research and development, will lead advancement of the company’s proprietary BiTAC(R) platform technologies for the development of cancer therapies targeting solid tumors. He succeeds Rick Austin, Ph.D., who will depart following a transition period.
Erkel brings two decades of experience in antibody therapeutics, antibody engineering and preclinical development, including prior leadership roles at MorphoSys AG, where he led immuno-oncology programs focused on T-cell engagers. VERAXA said his experience managing multidisciplinary research programs will support efforts to expand the company’s oncology pipeline and advance BiTAC(R) candidates toward clinical development.
At VERAXA, we are building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, we are rapidly advancing our pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.
BiTAC(R) is a registered trademark of VERAXA Biotech GmbH.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA
Greenland Mines (NASDAQ: GRML) announced its board of directors has adopted a limited-duration stockholder rights plan, effective July 22, 2026, to protect stockholders from coercive takeover tactics and ensure they receive full and fair value in connection with any proposal to acquire the company or obtain control. The rights plan will remain in effect for one year unless redeemed, exchanged or otherwise terminated earlier.
Under the plan, rights generally become exercisable if a person or group acquires beneficial ownership of 15% or more of the company’s outstanding common shares, with certain existing holders grandfathered under specified conditions. Greenland Mines said the plan is intended to provide the board with time to evaluate acquisition proposals and does not prevent it from considering or accepting offers determined to be in the best interests of stockholders.
Greenland Mines Ltd is a Nasdaq-listed company with two operating divisions: (1) Mining, focused on the exploration and development of the Skaergaard Project in southeast Greenland and, subject to closing of the previously announced transaction, the Sarfartoq neodymium-praseodymium (Nd-Pr) rare earths project in southwest Greenland; and (2) Biotech, including Klotho’s KLTO‑202 primary indication for ALS. The Company’s strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to GRML are available in the company’s newsroom at https://ibn.fm/GRML
Datavault AI (NASDAQ: DVLT) will host its first Analyst and Investor Day in New York City on Aug. 4, 2026, where management plans to outline the company’s strategic roadmap and demonstrate technologies supporting its AI-powered data monetization and real-world asset tokenization platform. The event will feature a live demonstration of the Information Data Exchange(R) (“IDE”), updates on the expansion of the SanQtum distributed GPU edge network and details surrounding the pending acquisition and planned integration of the NYIAX advertising exchange into Datavault AI’s broader blockchain ecosystem.
Management also expects to discuss the commercialization of its tokenization and exchange platforms, including agreements covering an estimated $800 million in real-world assets and the company’s target of at least $200 million in 2026 revenue. Additional presentations will focus on scaling the SanQtum network to approximately 48,000 GPUs across more than 100 U.S. cities by year-end, as well as plans to launch AI-enabled marketplaces for licensing and trading tokenized data, commodities, advertising, sports and entertainment rights and other digital and real-world assets during the second half of 2026.
Datavault AI(TM) is leading the way in AI-driven data experiences, valuation and monetization of assets in the Web 3.0 environment. The company’s cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic Sciences and Data Sciences divisions.
Datavault AI’s Acoustic Sciences division features WiSA(R), ADIO(R) and Sumerian(R) patented technologies and industry-first foundational spatial and multichannel wireless, high-definition sound transmission technologies with intellectual property covering audio timing, synchronization and multi-channel interference cancellation. The Data Science division leverages the power of Web 3.0 and high-performance computing to provide solutions for experiential data perception, valuation and secure monetization.
Datavault AI’s platform serves multiple industries, including high-performance computing software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy and more. The Information Data Exchange(R) enables Digital Twins and the licensing of name, image and likeness by securely attaching physical real-world objects to immutable metadata, fostering responsible AI with integrity. The company’s technology suite is fully customizable and offers AI- and machine-learning-based automation, third-party integration, detailed analytics and data, marketing automation and advertising monitoring.
The company is headquartered in Philadelphia, PA. Learn more about Datavault AI at https://dvlt.ai.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to DVLT are available in the company’s newsroom at https://ibn.fm/DVLT
The company has received Scientific Advice from Germany’s Paul-Ehrlich-Institute (“PEI”) supporting the proposed development strategy for its lead BiTAC(R)-TCE program.
The regulatory feedback provides early guidance on the company’s biological rationale, safety assessments, and non-clinical development plan, for its novel therapeutic platform.
VERAXA believes the advice helps reduce development uncertainty by providing greater clarity before advancing toward clinical studies.
The company’s lead BiTAC(R)-TCE candidate previously generated encouraging preclinical data presented at the 2026 American Association for Cancer Research (“AACR”) Annual Meeting.
VERAXA continues to build a diversified oncology pipeline that includes bispecific T-cell engagers, antibody-drug conjugates (“ADCs”) and other engineered antibody formats.
The latest regulatory milestone follows continued progress in manufacturing and development as the company advances next-generation antibody therapeutics for cancer.
VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has taken another step in the development of its proprietary BiTAC(R)-TCE platform after receiving Scientific Advice from Germany’s Paul-Ehrlich-Institute (“PEI”), providing regulatory feedback on the biological rationale and proposed non-clinical development strategy for its lead therapeutic program. The announcement, released on July 20, signals progress as the biotechnology company prepares its most advanced BiTAC(R)-TCE candidate for future clinical development (https://ibn.fm/zBiDU).
Scientific Advice procedures allow drug developers to consult with regulatory experts before clinical trials begin, helping companies align their development strategies with regulatory expectations regarding safety, tolerability and…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA
Beeline Holdings (NASDAQ: BLNE), a fast-growing digital mortgage platform offering a quicker and easier path to home ownership, was recently added as a member of the Russell Microcap Index. An article discussing this highlights the notable milestone for Beeline as it joins a group of small-cap companies tracked by institutional investors and index-linked funds. “Chief Executive Officer Nick Liuzza said the company expects the addition to improve trading liquidity and broaden investor exposure to the business,” reads the article.
“Beeline has spent the last several years positioning itself as a technology-focused alternative to traditional mortgage originators. Through its subsidiary, Beeline Loans Inc., the company offers conventional mortgages alongside non-qualified mortgage products tailored to borrowers who may not fit standard underwriting models. The company’s strategy increasingly centers on automation, artificial intelligence and digital self-service tools designed to reduce approval timelines and simplify the financing process. Beeline says its platform can close loans in roughly 14 to 21 days, materially below broader industry averages.”
Beeline is a technology-forward mortgage and fintech platform focused on AI-powered lending, title services, blockchain-enabled financial infrastructure, and digital real estate solutions. The company is developing next-generation mortgage and home equity products designed to modernize the residential finance market.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to BLNE are available in the company’s newsroom at https://ibn.fm/BLNE
This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.
Quantum BioPharma’s MS focus is Lucid-MS, a patented new chemical entity that takes a fundamentally different approach from existing therapies.
Supporting Lucid-MS’s phase 2 development is an ongoing imaging collaboration with Massachusetts General Hospital.
The company developed unbuzzd, a proprietary dietary supplement formulated to support alcohol metabolism and reduce the acute effects of intoxication and hangover.
Neurological disorders affect hundreds of millions of people worldwide, and for many of those patients, existing treatments fall far short. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company, is working to change that, with a pipeline targeting two significant areas of unmet neurological need: multiple sclerosis and the acute cognitive and physiological effects of alcohol intoxication.
Multiple sclerosis is one of the most common and debilitating neurological diseases affecting young adults. An estimated 2.9 million people are living with MS around the work; about one million of those living in the United States. The disease is most often diagnosed between ages 20 and 50, with a mean age of 32 globally, and affects females at roughly twice the rate of…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM
Datavault AI (NASDAQ: DVLT) announced that Fiserv (NASDAQ: FISV) will serve as the exclusive embedded financial services and payments provider for the company’s digital marketplaces and exchanges. Through Fiserv’s Embedded Finance platform, Datavault AI will integrate banking, payment and card programs into its ecosystem, supporting financial transactions across platforms including its planned NIL Exchange and patented Information Data Exchange(R).
The partnership is expected to provide athletes participating in Datavault AI’s NIL Exchange with payment wallets and debit cards to receive and manage name, image and likeness earnings, while buyers and sellers using the Information Data Exchange(R) will gain access to demand deposit accounts and card capabilities. The companies said the collaboration is designed to embed trusted financial infrastructure directly into Datavault AI’s marketplaces, streamlining commerce and expanding access to banking services for platform participants.
Datavault AI(TM) is leading the way in AI-driven data experiences, valuation and monetization of assets in the Web 3.0 environment. The company’s cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic Sciences and Data Sciences divisions.
Datavault AI’s Acoustic Sciences division features WiSA(R), ADIO(R) and Sumerian(R) patented technologies and industry-first foundational spatial and multichannel wireless, high-definition sound transmission technologies with intellectual property covering audio timing, synchronization and multi-channel interference cancellation. The Data Science division leverages the power of Web 3.0 and high-performance computing to provide solutions for experiential data perception, valuation and secure monetization.
Datavault AI’s platform serves multiple industries, including high-performance computing software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy and more. The Information Data Exchange(R) enables Digital Twins and the licensing of name, image and likeness by securely attaching physical real-world objects to immutable metadata, fostering responsible AI with integrity. The company’s technology suite is fully customizable and offers AI- and machine-learning-based automation, third-party integration, detailed analytics and data, marketing automation and advertising monitoring.
The company is headquartered in Philadelphia, PA. Learn more about Datavault AI at https://dvlt.ai.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to DVLT are available in the company’s newsroom at https://ibn.fm/DVLT
BOXABL is advancing a factory-based approach to housing that seeks to standardize production and improve cost efficiency in a traditionally fragmented industry.
The company is targeting a large addressable market supported by a significant housing supply gap and long-term affordability challenges.
Its modular system is designed to scale across multiple use cases, from individual homes to large residential and commercial developments.
The company is embedding automation and AI into factory operations to improve throughput, reduce defects, and optimize production efficiency.
BOXABL’s model pairs lower-margin home production with higher-margin service opportunities such as financing, insurance, and maintenance.
BOXABL (NASDAQ: BXBL) is a technology company focused on transforming residential construction through a factory-built, modular housing system designed for scale. By shifting homebuilding from traditional on-site processes to controlled manufacturing environments, the company aims to introduce a more standardized, efficient and repeatable approach to housing production. Its model integrates design, engineering and manufacturing into a unified system intended to improve speed, cost predictability and overall accessibility.
The company’s approach is rooted in addressing persistent structural challenges across the housing market, including affordability constraints, regulatory complexity and declining construction productivity. BOXABL’s platform is designed to streamline the building process by reducing reliance on fragmented workflows and enabling consistent output through automation and…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to BXBL are available in the company’s newsroom at https://ibn.fm/BXBL
Datavault AI (NASDAQ: DVLT) a provider of data monetization, credentialing, digital engagement and real-world asset tokenization technologies, outlined its strategic priorities for the third quarter of 2026, highlighting commercialization of its previously announced Project Qestrel ($QEST) token program, continued expansion of its SanQtum edge AI infrastructure and advancement of specialized digital asset exchange platforms. The company also expects to complete several previously announced transactions during the quarter, including the CyberCatch acquisition, the acquisition of NYIAX Inc. and the launch of the Data Vault Bank(R) brand through the targeted acquisition and renaming of a U.S. bank.
Datavault AI said its third-quarter objectives also include advancing tokenization initiatives for real-world assets, expanding blockchain transaction clearing partnerships and continuing development of AI-powered valuation, cybersecurity and data trust technologies. The company noted that several planned exchange platforms remain contingent on the evolution of U.S. digital asset legislation, including the proposed CLARITY Act, which has advanced through congressional committees but has not yet been enacted into law.
Datavault AI(TM) is leading the way in AI-driven data experiences, valuation and monetization of assets in the Web 3.0 environment. The company’s cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic Sciences and Data Sciences divisions.
Datavault AI’s Acoustic Sciences division features WiSA(R), ADIO(R) and Sumerian(R) patented technologies and industry-first foundational spatial and multichannel wireless, high-definition sound transmission technologies with intellectual property covering audio timing, synchronization and multi-channel interference cancellation. The Data Science division leverages the power of Web 3.0 and high-performance computing to provide solutions for experiential data perception, valuation and secure monetization.
Datavault AI’s platform serves multiple industries, including high-performance computing software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy and more. The Information Data Exchange(R) enables Digital Twins and the licensing of name, image and likeness by securely attaching physical real-world objects to immutable metadata, fostering responsible AI with integrity. The company’s technology suite is fully customizable and offers AI- and machine-learning-based automation, third-party integration, detailed analytics and data, marketing automation and advertising monitoring.
The company is headquartered in Philadelphia, PA. Learn more about Datavault AI at https://dvlt.ai.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to DVLT are available in the company’s newsroom at https://ibn.fm/DVLT
Forward Industries announced an expansion of its Solana treasury by over 500,000 Solana (SOL) during fiscal Q3 of 2026 at an average purchase price of around $79 per SOL.
This brings Forward’s SOL treasury up to 7.55 million SOL as of June 30, 2026.
During fiscal Q3, Forward sold 93,642 shares of common stock as part of its At The Market offering while delivering an annualized SOL-per-share growth of 36%.
Forward Industries (NASDAQ: FWDI), which continues to build and manage a large-scale Solana (SOL) treasury, announced that it acquired more than 500,000 SOL during fiscal Q3 of 2026, at an average purchase price of approximately $79 per SOL (https://nnw.fm/rOdBw).
This brings Forward’s SOL treasury up to 7.55 million SOL as of June 30, 2026, making it the largest SOL treasury company. Also during fiscal Q3 2026, as a part of its At The Market offering, Forward sold 93,642 shares of common stock while delivering an annualized SOL-per-share growth of 36%, which highlights…
NOTE TO INVESTORS: The latest news and updates relating to FWDI are available in the company’s newsroom at https://nnw.fm/FWDI
About NetworkNewsWire
NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer
VERAXA Biotech (NASDAQ: VRXA) announced it has received Scientific Advice from Germany’s Paul-Ehrlich-Institute regarding the underlying biology and proposed non-clinical development plan for its lead proprietary BiTAC-TCE cancer therapy program. The company said the regulatory feedback provides greater clarity on its proposed development strategy and indicates that the agency understands the biological rationale behind its dual-targeting, conditionally active BiTAC-TCE platform, representing an early step in advancing the program toward clinical development.
VERAXA also highlighted preclinical data presented at the American Association for Cancer Research Annual Meeting 2026 showing its lead BiTAC-TCE candidate selectively targeted cancer cells expressing both intended targets while sparing cells expressing only one target. According to the company, the studies demonstrated a favorable safety profile with efficacy comparable to a traditional T-cell engager, supporting the potential for an improved therapeutic index.
At VERAXA, we are building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, we are rapidly advancing our pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.
BiTAC(R) is a registered trademark of VERAXA Biotech GmbH.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA
BOXABL (NASDAQ: BXBL), a technology company focused on modular housing, began trading today on the Nasdaq Stock Market under the ticker symbol “BXBL” following the completion of its previously announced business combination with FG Merger II Corp. (NASDAQ: FGMC) and stockholder approval. The company said the listing marks its transition to a publicly traded company.
BOXABL said it has raised more than $230 million from over 50,000 investors to support its mission of modernizing home construction with affordable, factory-built housing. Its product lineup includes the 361-square-foot Casita, which unfolds on-site in under an hour and features a full kitchen, bathroom and utilities, as well as the 120-square-foot Baby Box. The company is also developing stackable and connectable modular units designed for larger residential applications, including townhomes and multifamily housing.
BOXABL is transforming the housing market with its modular building systems designed to deliver affordable, high-quality homes at unprecedented speed. Founded in 2017, BOXABL’s innovative approach has attracted worldwide attention as it aims to solve housing challenges for individuals and communities alike. BOXABL’s flagship product, the Casita, is a 361 square foot studio unit with a full kitchen, bathroom, and utilities. The Casita unfolds on-site in less than an hour and is manufactured inside BOXABL’s facilities. BOXABL also has announced the Baby Box, a smaller 120 square foot unit built to RV code, intended for simpler, no foundation setups. BOXABL is also developing stackable and connectable box models that can be combined to form townhomes, multifamily units, or larger single-family homes.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to BXBL are available in the company’s newsroom at https://ibn.fm/BXBL
Greenland Mines issued more than 12 million common shares to AnorTech, valued at approximately $3.5 million at closing.
Anorthosite is a rock type abundant in Greenland and on the moon, and AnorTech is developing proprietary processes to extract high-value materials from it.
The transaction moves Greenland closer to the midstream segment of the critical materials value chain.
Two companies with deep roots in Greenland’s mineral landscape have formalized a relationship that could reshape how each of them is valued. Greenland Mines (NASDAQ: GRML) has closed a strategic share exchange with AnorTech Inc. (TSX-V: ANOR; OTCQB: ANORF), a deal that gives Greenland Mines its first foothold in midstream critical materials processing while giving AnorTech access to a NASDAQ-listed partner with growing capital markets presence and a portfolio of world-class Greenland assets.
The transaction, announced June 16 and formally closed by the end of the month, is structured as a share exchange rather than a cash acquisition. Greenland Mines issued 12,400,000 of its common shares to AnorTech, valued at approximately $3.5 million at closing. In return, Greenland received…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to GRML are available in the company’s newsroom at https://ibn.fm/GRML
The company has appointed veteran medtech finance executive Sarah M. Romano as Chief Financial Officer, effective August 3, 2026.
Romano brings more than two decades of experience in public-company finance, capital markets, and medical technology, having raised more than $100 million during her career.
The appointment comes as SS Innovations continues pursuing U.S. FDA clearance for its SSi Mantra surgical robotic system while expanding internationally.
The company recently graduated the inaugural class of its SS International Centre for Robotics Surgery (“SSICRS”) cardiac robotic surgery training program.
SSICRS welcomed 33 healthcare professionals from seven countries, underscoring the company’s emphasis on surgeon education alongside technology deployment.
SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies, has appointed veteran medical technology finance executive Sarah M. Romano as chief financial officer, adding public-company financial and capital markets experience as the surgical robotics developer continues its global expansion and advances regulatory initiatives. The appointment, effective August 3, comes at a time when SS Innovations is pursuing broader commercialization of its SSi Mantra robotic surgical platform while continuing preparations for U.S. Food and Drug Administration review (https://nnw.fm/yY4UM).
Romano joins SS Innovations after serving as chief financial officer at Vicarious Surgical, another developer of robotic surgical technologies, where she oversaw financial and operational initiatives designed to reduce cash burn, strengthen the company’s balance sheet and support…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII
Datavault AI (NASDAQ: DVLT), a provider of data monetization, credentialing, digital engagement and real-world asset (“RWA”) tokenization technologies, has appointed Dr. Barry Childe as chief information security officer. In the role, Childe will lead the company’s cybersecurity strategy, strengthen data protection across its tokenization, valuation and secure data monetization platforms and oversee initiatives focused on AI security and quantum-resistant technologies.
Childe brings more than 40 years of experience in cybersecurity, high-performance computing, cloud infrastructure and distributed-ledger technology, including leadership positions at HSBC, Barclays Capital, The Royal Bank of Scotland and VMware, as well as co-founding quantum-encryption company Arqit. CEO Nathaniel T. Bradley said Childe’s expertise in cryptography, high-performance computing and quantum-resistant security will help support the company’s secure infrastructure as it expands its tokenization, valuation and data monetization platforms.
Datavault AI(TM) is leading the way in AI-driven data experiences, valuation and monetization of assets in the Web 3.0 environment. The company’s cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic Sciences and Data Sciences divisions.
Datavault AI’s Acoustic Sciences division features WiSA(R), ADIO(R) and Sumerian(R) patented technologies and industry-first foundational spatial and multichannel wireless, high-definition sound transmission technologies with intellectual property covering audio timing, synchronization and multi-channel interference cancellation. The Data Science division leverages the power of Web 3.0 and high-performance computing to provide solutions for experiential data perception, valuation and secure monetization.
Datavault AI’s platform serves multiple industries, including high-performance computing software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy and more. The Information Data Exchange(R) enables Digital Twins and the licensing of name, image and likeness by securely attaching physical real-world objects to immutable metadata, fostering responsible AI with integrity. The company’s technology suite is fully customizable and offers AI- and machine-learning-based automation, third-party integration, detailed analytics and data, marketing automation and advertising monitoring.
The company is headquartered in Philadelphia, PA. Learn more about Datavault AI at https://dvlt.ai.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to DVLT are available in the company’s newsroom at https://ibn.fm/DVLT
SS Innovations International (NASDAQ: SSII) announced its SSi Mantra surgical robotic system will be featured at the 2026 Society of Robotic Surgery Annual Meeting, July 23-26 in Hollywood, Florida. The system will be displayed throughout the event, highlighted in multiple breakout sessions and used in a live broadcast of a remote partial nephrectomy performed by Dr. Amitabh Singh from the company’s headquarters in Gurugram, India, on a patient at Rajeev Gandhi Cancer Institute and Research Centre in New Delhi.
Chairman and CEO Dr. Sudhir Srivastava will participate as a speaker and panelist in multiple sessions covering telesurgery, robotic surgery adoption, regulatory frameworks and global access to robotic care. As of July 6, 2026, the SSi Mantra system had been used in 12,375 procedures spanning more than 170 procedure types, including 653 cardiac procedures, 178 telesurgeries and 225 pediatric surgeries, while approximately 2,100 physicians have been trained on the platform.
SS Innovations International, Inc. develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of surgical robotic procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII
Datavault AI (NASDAQ: DVLT) announced it will tokenize and monetize Available Infrastructure’s Project Qestrel, a nationwide network of cybersecure edge data centers deploying across the United States, using its Information Data Exchange(R) platform and patented tokenization technology. The companies expect the Project Qestrel token ($QEST) program to represent more than $1 billion in tokenized value upon full deployment, providing access and usage rights across the edge AI infrastructure network while supporting secondary market trading. Initial token offerings are targeted for the third quarter of 2026.
Project Qestrel is expected to deploy 1,000 cybersecure edge data centers across 100 U.S. cities and more than 30 states as part of an approximately $5 billion buildout. Datavault AI said the initiative expands its existing relationship with Available Infrastructure and will generate revenue through an equal-sharing arrangement, with Datavault AI providing tokenization, clearing, valuation and exchange services. The companies believe the program represents the industry’s first large-scale tokenization of a live-deploying nationwide edge AI infrastructure network, creating a new digital asset class tied to AI compute capacity.
Datavault AI(TM) is leading the way in AI-driven data experiences, valuation and monetization of assets in the Web 3.0 environment. The Company’s cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic Sciences and Data Sciences divisions.
Datavault AI’s Acoustic Sciences division features WiSA(R), ADIO(R) and Sumerian(R) patented technologies and industry-first foundational spatial and multichannel wireless, high-definition sound transmission technologies with intellectual property covering audio timing, synchronization and multi-channel interference cancellation. The Data Science division leverages the power of Web 3.0 and high-performance computing to provide solutions for experiential data perception, valuation and secure monetization.
Datavault AI’s platform serves multiple industries, including high-performance computing software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy and more. The Information Data Exchange(R) enables Digital Twins and the licensing of name, image and likeness by securely attaching physical real-world objects to immutable metadata, fostering responsible AI with integrity. The Company’s technology suite is fully customizable and offers AI- and machine-learning-based automation, third-party integration, detailed analytics and data, marketing automation and advertising monitoring.
The Company is headquartered in Philadelphia, PA. Learn more about Datavault AI at https://dvlt.ai.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to DVLT are available in the company’s newsroom at https://ibn.fm/DVLT
Regentis Biomaterials (NYSE American: RGNT) announced it has received approval from the European Notified Body to manufacture GelrinC(R) using its next-generation solvent-free manufacturing process, a milestone that supports the product’s planned commercial launch in Europe. The company said the new process increases production yield by approximately 400%, producing five times more product from the same manufacturing volume while improving manufacturing efficiency, scalability and occupational and environmental safety. Extensive clinical testing validated consistent product quality and clinical performance.
GelrinC(R), which has already received CE Mark approval in Europe, is a proprietary, cell-free hydrogel implant designed to regenerate cartilage through a minimally invasive 10-minute procedure. Regentis said commercialization will be supported through its expanding European Centers of Excellence, surgeon training programs and collaborations with leading orthopedic institutions, including Humanitas Research Hospital in Milan, targeting a U.S. cartilage repair market valued at approximately $3 billion.
Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic treatments, Regentis’ Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. Regentis’ lead product GelrinC(R), is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing the surrounding cells to regenerate the cartilage in a controlled and synchronous process. GelrinC(R) aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available.
This content has been disseminated on behalf of Regentis Biomaterials Ltd. (NYSE American: RGNT) as part of a paid investor awareness and marketing engagement.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to RGNT are available in the company’s newsroom at https://ibn.fm/RGNT
Greenland Mines (NASDAQ: GRML) announced that independent consultant SLR Consulting (Canada) Ltd. has completed the first U.S. Securities and Exchange Commission S-K 1300-compliant Technical Report Summary for the Skaergaard project in southeast Greenland, featuring an updated 2026 Mineral Resource Estimate effective July 3, 2026. The estimate increased indicated contained palladium equivalent (“PdEq”) metal by 31% to 15.0 million ounces, boosted indicated grade by 36% to 3.04 g/t PdEq and raised inferred contained PdEq metal by 24% to 17.49 million ounces compared with the project’s 2022 resource estimate.
The company said the upgraded resource reflects improved geological modeling and updated metal price assumptions, including gold at $3,500 per ounce, while providing the regulatory foundation to advance toward an Initial Assessment under S-K 1300. Greenland Mines also noted that its 2026 field program is underway with drilling, bulk sampling, engineering, environmental and geotechnical work designed to support evaluation of both open-pit and underground mining scenarios at the Skaergaard project.
Greenland Mines Ltd is a Nasdaq-listed company with two operating divisions: (1) Mining, focused on the exploration and development of the Skaergaard Project in southeast Greenland and, subject to closing of the previously announced transaction, the Sarfartoq neodymium-praseodymium (Nd-Pr) rare earths project in southwest Greenland; and (2) Biotech, including Klotho’s KLTO‑202 primary indication for ALS. The Company’s strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to GRML are available in the company’s newsroom at https://ibn.fm/GRML
Beeline Holdings (NASDAQ: BLNE), the fast-growing digital mortgage platform, announced it will host a stakeholder update call to discuss its second-quarter 2026 results on Thursday, Aug. 13, 2026, at 5 p.m. ET.
The call will be hosted by CEO Nick Liuzza and CFO Chris Moe, who will review the company’s quarterly performance and provide updates on ongoing initiatives.
Beeline Holdings, Inc. is a technology-driven mortgage and title platform focused on simplifying home financing through digital innovation, artificial intelligence, and automation. The Company provides residential mortgage lending, title services, and home equity solutions designed to improve efficiency and enhance the borrower experience.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to BLNE are available in the company’s newsroom at https://ibn.fm/BLNE
Zacks Investment Research recently initiated coverage of Versus Systems (NASDAQ: VS), citing the company’s progress in strengthening its financial performance and advancing its gamification and audience engagement platform. Zacks highlighted improved first-quarter 2026 results, including significantly reduced operating losses and positive operating cash flow, along with potential growth opportunities tied to an extension of Versus’ technology licensing relationship with ASPIS. The company’s Winfinite and Filter Fan Cam platforms combine interactive games, real-world rewards, and augmented reality experiences to help brands, sports organizations, and entertainment companies increase customer engagement across digital and live-event channels. With a growing international footprint and continued product development, Versus aims to capitalize on increasing demand for interactive marketing and fan engagement solutions.
Versus Systems is a leading provider of gamification and audience engagement technology. Its platform enables brands, teams, and entertainment partners to create rewarding interactive experiences that transform how they connect with consumers worldwide. For more information on Versus Systems and its engagement technologies, visit VersusSystems.com.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to VS are available in the company’s newsroom at https://ibn.fm/VSI
This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) was featured in a recent article that discussed its advancement of its proprietary multiple sclerosis therapy candidate, LUCID-MS, which is designed to target demyelination and protection or restoration of myelin integrity. The company reported that Phase 1 clinical studies in healthy volunteers demonstrated a favorable safety profile and that the therapy was generally well tolerated, supporting advancement into patient-focused studies. In April 2026, Quantum BioPharma submitted an Investigational New Drug application to the U.S. Food and Drug Administration for LUCID-MS, paving the way for a planned Phase 2 clinical trial in people living with multiple sclerosis. The company believes the therapy may offer a differentiated, potentially first-in-class approach because it aims to directly address myelin loss and neurodegeneration, rather than relying solely on immune modulation, while also strengthening operational support for the program through a planned partnership with Allucent and engagement with neurological specialists.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd and spun out its OTC version to a company, Unbuzzd Wellness Inc. (“UWI”), led by industry veterans. Quantum BioPharma retains ownership of 19.84% (as of March 31, 2026) of UWI at www.unbuzzd.com. The agreement with UWI also includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar product or alternative formulations specifically for pharmaceutical and medical uses.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM
Artificial intelligence is becoming an increasingly important tool for drug discovery, with major pharmaceutical companies expanding AI collaborations across oncology and immunology.
VERAXA Biotech has partnered with AI-focused contract research organization Ardigen to strengthen discovery efforts for its BiTAC(R) cancer therapy platform.
The collaboration aims to identify optimal dual-target combinations for T-cell engagers and antibody-drug conjugates while reducing development risks.
VERAXA’s Boolean “AND-gated” BiTAC(R) technology presents a use case that may be particularly well suited for AI-assisted target selection and therapeutic design.
AI analysis of historical clinical and preclinical datasets could help identify promising targets that were previously abandoned because of safety concerns.
The partnership reflects a broader trend toward combining computational biology with next-generation antibody therapeutics to improve research productivity.
Artificial intelligence is becoming an increasingly important component of pharmaceutical research, with companies using machine learning to analyze complex biological data, identify drug targets and improve clinical development decisions. Against that backdrop, VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, announced a collaboration with AI-focused research partner Ardigen that is intended to strengthen development of the company’s BiTAC(R) oncology platform through AI-enabled target discovery and validation (https://ibn.fm/yoDH5).
The agreement brings together VERAXA’s antibody engineering capabilities with Ardigen’s expertise in artificial intelligence, computational biology and bioinformatics. Ardigen, headquartered in Kraków, Poland, with U.S. operations in San Francisco, has supported more than 700 discovery projects for…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA
SS Innovations International (NASDAQ: SSII), a developer of surgical robotic technologies, has appointed Sarah M. Romano as chief financial officer, effective Aug. 3, 2026. Based in the United States, Romano brings more than two decades of finance leadership experience in the medical technology and life sciences sectors and will help lead the company’s financial operations as it advances its global expansion strategy, including pursuit of U.S. FDA approval for its SSi Mantra surgical robotic system.
Most recently, Romano served as chief financial officer of Vicarious Surgical, where she led financial and operational initiatives to reduce cash burn, strengthen the balance sheet and support strategic objectives. She previously held CFO roles at Entero Therapeutics and Kiora Pharmaceuticals, raising more than $100 million through public and private financings while overseeing strategic transactions, SEC reporting and investor relations.
SS Innovations International, Inc. develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of surgical robotic procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII
Datavault AI (NASDAQ: DVLT), a technology company focused on data valuation, monetization, governance, credentialing, digital asset infrastructure and enterprise information management solutions, has appointed CBIZ CPAs P.C. as its independent registered public accounting firm. The appointment underscores the company’s commitment to maintaining high standards of financial reporting, compliance and corporate governance as it continues supporting customers and stakeholders. Additional details regarding the appointment are available in the company’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission.
Datavault AI(TM) is leading the way in AI-driven data experiences, valuation and monetization of assets in the Web 3.0 environment. The Company’s cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic Sciences and Data Sciences divisions.
Datavault AI’s Acoustic Sciences division features WiSA(R), ADIO(R) and Sumerian(R) patented technologies and industry-first foundational spatial and multichannel wireless, high-definition sound transmission technologies with intellectual property covering audio timing, synchronization and multi-channel interference cancellation. The Data Science division leverages the power of Web 3.0 and high-performance computing to provide solutions for experiential data perception, valuation and secure monetization.
Datavault AI’s platform serves multiple industries, including high-performance computing software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy and more. The Information Data Exchange(R) enables Digital Twins and the licensing of name, image and likeness by securely attaching physical real-world objects to immutable metadata, fostering responsible AI with integrity. The Company’s technology suite is fully customizable and offers AI- and machine-learning-based automation, third-party integration, detailed analytics and data, marketing automation and advertising monitoring.
The Company is headquartered in Philadelphia, PA. Learn more about Datavault AI at https://dvlt.ai.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to DVLT are available in the company’s newsroom at https://ibn.fm/DVLT
Affordability and accessibility remain the company’s core priorities as it expands its surgical robotics platform globally, with artificial intelligence, automation, and new robotic platforms, remaining central to the company’s long-term product roadmap.
Telesurgery and teleproctoring are becoming important differentiators, allowing expert surgeons to support complex procedures remotely.
The SSi Mantra system was designed to reduce the cost of robotic surgery while supporting multiple specialties, including cardiac surgery.
The company has installed more than 200 robotic systems and completed more than 11,700 robotic procedures, including over 170 telesurgeries.
SS Innovations is pursuing FDA and European regulatory approvals while expanding into additional international markets.
For investors evaluating emerging medical technology companies, the competitive advantages behind a product can be as important as financial results. That was the focus of a recent Medsider interview with Dr. Sudhir Srivastava, founder, chairman and CEO of SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies, who discussed the company’s strategy to broaden access to robotic surgery through lower-cost technology, physician training and remote surgical capabilities.
Rather than concentrating solely on competing with existing robotic surgery platforms, Dr. Srivastava described SS Innovations’ objective as expanding access to hospitals and patients that have historically been unable to adopt robotic surgery because of equipment costs and operating…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII
Safe Pro Group (NASDAQ: SPAI) announced it has been selected by AFWERX for a Small Business Innovation Research (“SBIR”) contract to develop a new artificial intelligence dataset using images of foreign object debris and damage (“FOD”) commonly found on U.S. Air Force and civilian airfields. The project is intended to support Department of the Air Force initiatives while expanding the company’s AI-powered computer vision technology into defense and commercial airfield operations.
The company said the award broadens the potential applications of its patented SPOTD (Safe Pro Object Threat Detection) platform beyond battlefield and post-conflict landmine detection. The contract follows recent interest from the U.S. Army, which has invited Safe Pro to provide operational support during an upcoming airfield exercise.
Safe Pro Group showcases the latest application of its AI-powered threat detection technology, demonstrating how its real-time computer vision platform can support rapid inspection of airfields and runways. Designed to autonomously identify landmines, unexploded ordnance (UXO) and other potential hazards, the technology enhances situational awareness and helps improve safety across defense and critical infrastructure operations.
About Safe Pro Group Inc.
Safe Pro Group Inc. is a mission-driven technology company delivering AI-enabled security and defense solutions. Through cutting-edge platforms like SPOTD, Safe Pro provides advanced situational awareness tools for defense, humanitarian, and homeland security applications globally. The Company is a leading provider of artificial intelligence (AI) solutions specializing in drone imagery processing, leveraging commercially available off-the-shelf drones with its proprietary machine learning and computer vision technology to enable rapid identification of explosive threats, providing a safer and more efficient alternative to traditional human-based analysis methods. Built on a cloud-based ecosystem and powered by Amazon Web Services (AWS), Safe Pro Group’s scalable platform targets multiple markets, including commercial, government, law enforcement, and humanitarian sectors where its Safe Pro AI software, Safe-Pro USA protective gear, and Airborne Response drone-based services can work in synergy to deliver safety and operational efficiency.
NOTE TO INVESTORS: The latest news and updates relating to SPAI are available in the company’s newsroom at http://ibn.fm/SPAI
About DefenseWireNews
DefenseWireNews (“DWN”) is a specialized communications platform with a focus on defense contractors, aerospace firms, cybersecurity leaders, advanced manufacturing innovators, and other mission-critical companies operating at the intersection of public markets and government demand. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, DWN is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, DWN brings its clients unparalleled recognition and brand awareness. DWN is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from DefenseWireNews, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
VERAXA Biotech (NASDAQ: VRXA) announced a collaboration with AI-driven bioinformatics company Ardigen S.A. to support development of its BiTAC(R) pipeline of T-cell engagers and future antibody-drug conjugates. The partnership will initially focus on developing AI-enabled tools to identify and prioritize synergistic dual-target combinations for VERAXA’s BiTAC platform, which is designed to improve tumor targeting while reducing off-target toxicity.
VERAXA said integrating artificial intelligence into its research and development strategy could enhance target selection by analyzing large preclinical and clinical datasets, including programs that demonstrated efficacy but failed because of toxicity. The company believes the collaboration will strengthen development of precision oncology therapies and improve long-term drug development success rates.
At VERAXA, we are building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, we are rapidly advancing our pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.
BiTAC(R) is a registered trademark of VERAXA Biotech GmbH.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA
Wrap Technologies (NASDAQ: WRAP) announced it entered the third quarter of 2026 with approximately $1.2 million in international orders from customers in Brazil and India, with the associated revenue expected to be recognized during the quarter. The company said the orders reflect expanding international adoption of its BolaWrap(R) 150 restraint device and were secured before increased customer interest following the recent ATF ruling classifying the product as an instrument of restraint rather than a firearm or “any other weapon.”
Wrap said the combination of repeat international orders, growing global demand and the favorable regulatory change positions the company for a potentially strong second half of 2026. The company reaffirmed its target of approximately 100% year-over-year revenue growth for 2026, citing expanding international deployments, repeat customer activity and a growing commercial pipeline.
Wrap Technologies, Inc. a global leader in innovative public safety technologies and non-lethal tools, delivering cutting-edge technology with exceptional people to address the complex, modern day challenges facing public safety organizations.
WRAP’s complete public safety portfolio includes the non-lethal BolaWrap(R) 150 device, Wrap Reality(R) immersive training platform, WrapVision(TM) body-worn camera system, WrapTactics(TM) training programs, and next-generation C-UAS solutions like PAN-DA and the 1KC Kinetic Anti-Drone Cassette, all of which supports the Company’s mission to provide safer, scalable, and cost-effective technologies for public safety, defense, and critical infrastructure markets.
With a growing demand for non-lethal tools and techniques to create time, distance and tactical advantage in non-criminal calls, Wrap’s BolaWrap(R) 150 incorporates a multi-sensory distraction of sight and sound as a first response, followed by a non-lethal restraint if further escalation is required. This approach reduces the risk of injury to officers, subjects, and the community.
Wrap’s BolaWrap(R) 150 solution is intended to provide law enforcement with a safer choice for nearly every phase of a critical incident. This innovative, patented device deploys a multi-sensory, cognitive disruption to expand the pre-escalation period and gives officers the advantage and critical time to manage non-compliant subjects before resorting to higher-force options. The BolaWrap(R) 150 is not pain-based compliance. It does not shoot, strike, shock, or incapacitate, instead, it helps officers strategically operate pre-escalation on the force continuum, reducing the risk of injury to both officers and subjects. Used by over 1,000 agencies across the U.S. and in 60 countries, BolaWrap(R) is backed by training certified by the International Association of Directors of Law Enforcement Standards and Training (IADLEST), reinforcing Wrap’s commitment to public safety through cutting-edge technology and expert training.
WrapReality(TM) VR is a fully immersive training simulator to enhance decision-making under stress.
As a comprehensive public safety training platform, it provides first responders with realistic, interactive scenarios that reflect the evolving challenges of modern law enforcement. By offering a growing library of real-world situations, WrapReality(TM) is intended to equip officers with the skills and confidence to navigate high stakes encounters effectively, which we believe leads to safer outcomes for both responders and the communities they serve.
WrapVision is an all-new body-worn camera and evidence management system built for efficiency.
Designed for efficiency, security, and transparency to meet the rigorous demands of modern law enforcement, WrapVision captures, stores, and helps manage digital evidence, ensuring operational security, regulatory compliance, and enhanced video picture quality and field of view.
The WrapVision camera, powered by IONODES, boasts streamlined cloud integration and final North American assembly, with a critical made-in-America roadmap projected for early 2026. This track helps ensure data integrity and helps eliminate critical concerns over unauthorized access or foreign surveillance risks.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to WRAP are available in the company’s newsroom at https://ibn.fm/WRAP
The renewed focus on energy security stems from ongoing concerns surrounding the Strait of Hormuz, one of the world’s most important energy transportation corridors.
For companies such as Greenland Energy Company that are pursuing new exploration opportunities outside traditional producing regions, these developments can strengthen the investment case for frontier projects.
The company’s upcoming drilling program in the Jameson Land Basin represents the first modern effort to fully test portions of the basin using contemporary exploration techniques.
In reaction to the ongoing conflict within the Middle East, the global energy market has once again been reminded how quickly geopolitical events can disrupt oil supplies and drive volatility across economies. Discussions surrounding the Strait of Hormuz and the strategic importance of new oil-producing regions have highlighted the need for diversified energy sources, creating a potentially favorable backdrop for Greenland Energy (NASDAQ: GLND), which is advancing exploration activities in Greenland’s Jameson Land Basin and seeking to unlock a significant frontier oil resource.
The renewed focus on energy security stems from ongoing concerns surrounding the Strait of Hormuz, one of the world’s most important energy transportation corridors. Roughly one-fifth of global petroleum liquids consumption moves through the narrow waterway connecting the Persian Gulf to…
This communication contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995 and within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained herein other than statements of present or historical fact, including, without limitation, statements regarding Greenland Energy Company’s (the “Company”) future financial performance, business strategy, operations, financial position, estimated revenues and losses, projected costs, prospects, plans, objectives of management, and expected benefits of the Company’s recent business combination, are forward-looking statements. Forward-looking statements are generally identified by the use of words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “project,”“forecast,” “potential,” “predict,” or the negative of these terms or similar expressions, although not all forward-looking statements contain such identifying words.
These forward-looking statements are based on management’s current expectations, assumptions and beliefs regarding future events and are based on information currently available to the Company. These statements involve a number of risks and uncertainties, many of which are difficult to predict and are beyond the Company’s control, and actual results may differ materially from those expressed or implied by these forward-looking statements. Factors that could cause actual results to differ materially include, among others: (i) Exploration and Geological Risks, including the Company’s status as a development-stage company with no operating history, revenues, or proved reserves; the inherent uncertainty in prospective resource estimates, including that the 13 billion barrel estimate is based on undiscovered accumulations with no certainty of discovery or commercial viability; geological complexity arising from limited seismic data coverage, pervasive igneous intrusions, faulting patterns, and significant Tertiary uplift creating thermal maturity uncertainty; the fact that the basin has never produced a commercial discovery despite decades of study dating back to the 1970s, and a 2008 USGS report stating less than a 10% chance of containing a technically recoverable hydrocarbon accumulation; and high-cost frontier exploration with estimated well costs of $40 million for the first well and $20 million for subsequent wells; (ii) Operational and Environmental Risks, including the challenges of operating in a remote Arctic location with extreme climate, harsh weather, limited daylight, no existing infrastructure, and seasonal access windows for equipment and personnel; drilling hazards such as blowouts, equipment failures, well control events, environmental releases, and accidents inherent in oil and gas operations; reliance on third-party contractors; and climate change scrutiny, as operations in Greenland face increasing opposition from environmental groups and institutional investors due to Arctic drilling concerns; (iii) Regulatory and Political Risks, including the 2021 Greenland drilling moratorium, and while licenses are grandfathered, future regulatory changes could jeopardize operations; geopolitical tensions, including U.S. interest in acquiring Greenland and Greenland’s internal independence movements that could affect operations; permit requirements, as drilling requires Environmental Impact Assessment approval and Field Activities Application approval from Greenlandic authorities; and forfeiture risk, as failure to meet drilling milestones could result in loss of the Company’s right to earn working interests; (iv) Financial and Capital Risks, including significant capital requirements and the need for substantial funding beyond current resources to complete the drilling program; commodity price volatility, as oil, gas, and NGL prices are highly volatile and will heavily influence project viability; a long development timeline during which market conditions may change significantly before potential production, unlike short-cycle shale projects; going concern uncertainty and substantial doubt about the Company’s ability to continue as a going concern without additional financing; and energy transition risk, as global demand for oil may decline due to electric vehicle adoption, renewable energy policies, and changing consumer preferences; and other risks and uncertainties as set forth in the Company’s Prospectus filed with the Securities and Exchange Commission pursuant to Rule 424(b)(4) under the Securities Act on April 29, 2026, in the section titled “Risk Factors”.
Forward-looking statements speak only as of the date they are made. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to GLND are available in the company’s newsroom at https://ibn.fm/GLND
Safe Pro Group (NASDAQ: SPAI), a tech company that delivers AI-powered security and defense solutions, recently announced strong first-quarter 2026 results, with revenue increasing 560% year over year to more than $1.22 million, as well as a 2,400% surge in high-margin revenue largely from sales of its AI-driven and drone-based video and image analysis solutions. The company posted consolidated gross margins exceeding 68%, ended the quarter with $14.8 million in cash and minimal debt, and continued executing on key operational initiatives, including delivering Edge processing systems and expanding support services under a U.S. government contract and contract modification. Safe Pro also reported growing interest in its NODE and NODE-X Edge AI solutions following U.S. Army demonstrations and strengthened its development efforts by launching a new Growth Team, led by Chief Growth Officer Brian Mack and VP of Government Growth Benjamin Chitty, to pursue additional U.S. government contract opportunities through teaming agreements with prime contractors.
Safe Pro Group is a mission-driven technology company delivering AI-enabled security and defense solutions. Through cutting-edge platforms like SPOTD, Safe Pro provides advanced situational awareness tools for defense, humanitarian, and homeland security applications globally. It is a leading provider of artificial intelligence (“AI”) solutions specializing in drone imagery processing leveraging commercially available “off-the-shelf” drones with its proprietary machine learning and computer vision technology to enable rapid identification of explosives threats, providing a much safer and more efficient alternative to traditional human-based analysis methods. Built on a cloud-based ecosystem and powered by Amazon Web Services (“AWS”), Safe Pro Group’s scalable platform is targeting multiple markets that include commercial, government, law enforcement and humanitarian sectors where its Safe Pro AI software, Safe-Pro USA protective gear and Airborne Response drone-based services can work in synergy to deliver safety and operational efficiency.
NOTE TO INVESTORS: The latest news and updates relating to SPAI are available in the company’s newsroom at https://ibn.fm/SPAI
About DefenseWireNews
DefenseWireNews (“DWN”) is a specialized communications platform with a focus on defense contractors, aerospace firms, cybersecurity leaders, advanced manufacturing innovators, and other mission-critical companies operating at the intersection of public markets and government demand. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, DWN is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, DWN brings its clients unparalleled recognition and brand awareness. DWN is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from DefenseWireNews, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
Wrap Technologies (NASDAQ: WRAP) issued a letter to stockholders outlining its strategy to evolve from a single-product company into an integrated public safety technology platform focused on artificial intelligence, advanced sensing, autonomous decision support and measured, non-lethal response. The company said its WrapShield(TM) platform is designed to integrate threat detection, classification, decision support and proportionate response across applications including law enforcement, border security, critical infrastructure, transportation and defense support.
Wrap said key milestones supporting its strategy include a favorable Bureau of Alcohol, Tobacco, Firearms and Explosives ruling classifying the BolaWrap(R) 150 as an instrument of restraint rather than a firearm, as well as its investment in Frenel Imaging Ltd. and exclusive U.S. and NATO commercialization rights for the company’s thermal-polarimetric sensing technology. Management also cited expanding customer adoption, growing international partnerships, increased bookings and continued investments in technology as positioning the company for long-term growth.
Wrap Technologies, Inc. a global leader in innovative public safety technologies and non-lethal tools, delivering cutting-edge technology with exceptional people to address the complex, modern day challenges facing public safety organizations.
WRAP’s complete public safety portfolio includes the non-lethal BolaWrap(R) 150 device, Wrap Reality(R) immersive training platform, WrapVision(TM) body-worn camera system, WrapTactics(TM) training programs, and next-generation C-UAS solutions like PAN-DA and the 1KC Kinetic Anti-Drone Cassette, all of which supports the Company’s mission to provide safer, scalable, and cost-effective technologies for public safety, defense, and critical infrastructure markets.
With a growing demand for non-lethal tools and techniques to create time, distance and tactical advantage in non-criminal calls, Wrap’s BolaWrap(R) 150 incorporates a multi-sensory distraction of sight and sound as a first response, followed by a non-lethal restraint if further escalation is required. This approach reduces the risk of injury to officers, subjects, and the community.
Wrap’s BolaWrap(R) 150 solution is intended to provide law enforcement with a safer choice for nearly every phase of a critical incident. This innovative, patented device deploys a multi-sensory, cognitive disruption to expand the pre-escalation period and gives officers the advantage and critical time to manage non-compliant subjects before resorting to higher-force options. The BolaWrap(R) 150 is not pain-based compliance. It does not shoot, strike, shock, or incapacitate, instead, it helps officers strategically operate pre-escalation on the force continuum, reducing the risk of injury to both officers and subjects. Used by over 1,000 agencies across the U.S. and in 60 countries, BolaWrap(R) is backed by training certified by the International Association of Directors of Law Enforcement Standards and Training (IADLEST), reinforcing Wrap’s commitment to public safety through cutting-edge technology and expert training.
WrapReality(TM) VR is a fully immersive training simulator to enhance decision-making under stress.
As a comprehensive public safety training platform, it provides first responders with realistic, interactive scenarios that reflect the evolving challenges of modern law enforcement. By offering a growing library of real-world situations, WrapReality(TM) is intended to equip officers with the skills and confidence to navigate high stakes encounters effectively, which we believe leads to safer outcomes for both responders and the communities they serve.
WrapVision is an all-new body-worn camera and evidence management system built for efficiency.
Designed for efficiency, security, and transparency to meet the rigorous demands of modern law enforcement, WrapVision captures, stores, and helps manage digital evidence, ensuring operational security, regulatory compliance, and enhanced video picture quality and field of view.
The WrapVision camera, powered by IONODES, boasts streamlined cloud integration and final North American assembly, with a critical made-in-America roadmap projected for early 2026. This track helps ensure data integrity and helps eliminate critical concerns over unauthorized access or foreign surveillance risks.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to WRAP are available in the company’s newsroom at https://ibn.fm/WRAP
Greenland Mines (NASDAQ: GRML) announced that IP Australia has granted Australian Patent No. 2023252508 covering gene therapy technology exclusively licensed by the company’s Biotech Division for the treatment of neuromuscular diseases through expression of the human Klotho protein. The patent strengthens the intellectual property supporting Greenland Mines’ Klotho-based therapeutic platform and includes claims covering gene therapy constructs, neuronal and induced pluripotent stem cells, and viral and non-viral delivery systems. The company said the patent further supports development of its KLTO-202 program targeting amyotrophic lateral sclerosis (“ALS”) and other neuromuscular disorders.
Greenland Mines Ltd is a Nasdaq-listed company with two operating divisions: (1) Mining, focused on the exploration and development of the Skaergaard Project in southeast Greenland and, subject to closing of the previously announced transaction, the Sarfartoq neodymium-praseodymium (Nd-Pr) rare earths project in southwest Greenland; and (2) Biotech, including Klotho’s KLTO‑202 primary indication for ALS. The Company’s strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to GRML are available in the company’s newsroom at https://ibn.fm/GRML
This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is a biopharmaceutical company focused on developing therapies and biotech solutions targeting neurodegenerative, metabolic and alcohol misuse disorders. QNTM was highlighted in a recent article discussing its advancement of a diversified platform spanning clinical-stage therapeutics, consumer-focused wellness products and strategic investments designed to address areas of significant unmet need. The publication reads, “The company’s strategy combines pharmaceutical research and development with commercialization partnerships and licensing structures intended to support multiple potential revenue streams and long-term growth initiatives. Quantum BioPharma is advancing programs across multiple stages of development while leveraging scientific research, intellectual property and commercial relationships as part of its broader business strategy.”
Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented UNBUZZD(TM) and spun out its OTC version to a company, Unbuzzd Wellness Inc. (“Unbuzzd”) (formerly, Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.84% (as of March 31, 2026) of Unbuzzd at www.unbuzzd.com. The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM
Datavault AI (NASDAQ: DVLT) announced it has signed a three-party joint venture agreement with Unity Reserve Holdings L.L.C. and Mandela Dlamini & Manaway L.L.C. forming Mandela Digital, the venture developing the proposed Mandela Dollar (“MUSD”), a 1:1 U.S. dollar-backed stablecoin focused on expanding financial inclusion across underserved markets. Under the agreement, Datavault AI will serve as Mandela Digital’s founding and exclusive technology partner, providing its AI-powered data monetization, tokenization and compliance platforms to support MUSD issuance, redemption, proof-of-reserve transparency and regulatory infrastructure.
The company said the joint venture formalizes an initiative first announced in February 2026 and is designed to pair advanced digital financial infrastructure with the legacy of Nelson Mandela. Datavault AI said its role extends beyond launch, with recurring technology responsibilities tied to MUSD operations, while positioning the deployment as a reference platform for future digital currency and real-world asset tokenization opportunities.
Datavault AI(TM) is leading the way in AI-driven data experiences, valuation and monetization of assets in the Web 3.0 environment. The company’s cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic Sciences and Data Sciences divisions.
Datavault AI’s Acoustic Sciences division features WiSA(R), ADIO(R) and Sumerian(R) patented technologies and industry-first foundational spatial and multichannel wireless, high-definition sound transmission technologies with intellectual property covering audio timing, synchronization and multi-channel interference cancellation. The Data Science division leverages the power of Web 3.0 and high-performance computing to provide solutions for experiential data perception, valuation and secure monetization.
Datavault AI’s platform serves multiple industries, including high-performance computing software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy and more. The Information Data Exchange(R) enables Digital Twins and the licensing of name, image and likeness by securely attaching physical real-world objects to immutable metadata, fostering responsible AI with integrity. The company’s technology suite is fully customizable and offers AI- and machine-learning-based automation, third-party integration, detailed analytics and data, marketing automation and advertising monitoring.
The company is headquartered in Philadelphia, PA. Learn more about Datavault AI at https://dvlt.ai.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to DVLT are available in the company’s newsroom at https://ibn.fm/DVLT
Datavault AI (NASDAQ: DVLT) announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for all 24 claims in its patent application covering blockchain-based methods and systems designed to detect and mitigate naked and excessive short selling through tokenized dividend distribution. The allowed claims include technologies for issuing digital dividend tokens on a distributed ledger, reconciling token issuance with reported share positions to identify settlement discrepancies, automating settlement and share recalls, supporting CUSIP reclassification, and providing real-time reporting and audit capabilities. The company said the intellectual property expands its blockchain and tokenization portfolio while creating potential licensing opportunities for exchanges, transfer agents, broker-dealers, custodians, issuers and digital asset platforms.
Datavault AI(TM) is leading the way in AI-driven data experiences, valuation and monetization of assets in the Web 3.0 environment. The Company’s cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic Sciences and Data Sciences divisions.
Datavault AI’s Acoustic Sciences division features WiSA(R), ADIO(R) and Sumerian(R) patented technologies and industry-first foundational spatial and multichannel wireless, high-definition sound transmission technologies with intellectual property covering audio timing, synchronization and multi-channel interference cancellation. The Data Science division leverages the power of Web 3.0 and high-performance computing to provide solutions for experiential data perception, valuation and secure monetization.
Datavault AI’s platform serves multiple industries, including high-performance computing software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy and more. The Information Data Exchange(R) enables Digital Twins and the licensing of name, image and likeness by securely attaching physical real-world objects to immutable metadata, fostering responsible AI with integrity. The Company’s technology suite is fully customizable and offers AI- and machine-learning-based automation, third-party integration, detailed analytics and data, marketing automation and advertising monitoring.
The Company is headquartered in Philadelphia, PA. Learn more about Datavault AI at https://dvlt.ai.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to DVLT are available in the company’s newsroom at https://ibn.fm/DVLT
The transaction brings the technology that already powers key components of Beeline mortgage platform fully in-house and is intended to accelerate AI deployment across mortgage origination, title operations, and future digital real estate products.
Beeline continues to position itself as a technology-focused mortgage platform, serving both traditional homebuyers and real estate investors through digital lending tools.
Beeline’s AI-powered customer assistant Bob has already demonstrated measurable business results, contributing to an 8% increase in lead-to-lock mortgage conversions when customers engage with the platform.
The MagicBlocks acquisition gives Beeline greater control over AI development, while MagicBlocks will continue licensing its technology to third-party financial institutions.
Beeline Holdings (NASDAQ: BLNE), a fast-growing digital mortgage platform offering a quicker and easier path to homeownership, has completed the acquisition of artificial intelligence company MagicBlocks, bringing the technology that already powers key components of its mortgage platform fully in-house.
The transaction gives Beeline complete ownership of the AI infrastructure behind Bob, the company’s proprietary artificial intelligence assistant, while providing greater control over future development across its mortgage origination and title businesses (https://ibn.fm/yG3Qc). According to Beeline, the…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to BLNE are available in the company’s newsroom at https://ibn.fm/BLNE
The company has initiated cell line development for its lead BiTAC(R) T-cell engager program, selecting ATUM to support manufacturing development as the candidate advances toward IND/CTA-enabling studies.
ATUM will apply its Leap-In Transposase(R) technology to generate stable clonal cell lines for VERAXA’s lead therapeutic candidate.
The collaboration represents an important development milestone, supporting manufacturing, analytical development and nonclinical studies required before clinical testing.
VERAXA’s BiTAC(R) platform is designed to improve the selectivity of T-cell engagers, potentially reducing toxicity associated with conventional approaches.
The company recently expanded its research facilities in Heidelberg, Germany, increasing laboratory capacity as multiple oncology programs move toward clinical development.
VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has begun cell line development for its lead BiTAC(R) T-cell engager (“BiTAC(R)-TCE”) program, marking another step in preparing the company’s most advanced oncology candidate for future clinical development.
The company announced that it has selected ATUM, a U.S.-based contract research organization specializing in bioengineering and cell line development, to generate stable clonal cell lines using its proprietary Leap-In Transposase(R) technology. According to VERAXA, the collaboration is intended to…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA
Differentiated SSi Mantra system attributes (e.g., cost advantages, cardiac and pediatric surgery capabilities, ease of use and training, and pioneering telesurgery features).
Large and growing addressable market with favorable industry tailwinds.
Stronghold in India, global expansion underway, and potential catalysts in the US and EU.
World-class R&D and manufacturing facilities to support growth.
Robust sales growth, expanding margins, and increasing mix of recurring revenue.
Aligned, accomplished management team and Board of Directors.
SS Innovations International (NASDAQ: SSII) develops differentiated surgical robotic technologies, highlighted by its advanced, cost-efficient SSi Mantra surgical robotic system. Spearheaded by a team of visionary engineers and Dr. Sudhir Srivastava, an acclaimed robotic cardiac surgeon and the company’s founder, Chairman and Chief Executive Officer, the SSi Mantra features differentiated capabilities in areas such as telesurgery, cardiac surgery and pediatric procedures. The SSi Mantra’s broad-based surgical robotic applications, modularity, user friendliness, training capabilities, clinical track record and relative cost advantages have contributed to its early commercial success.
SS Innovations is a rapidly growing American company headquartered in India and expanding globally with an eye on democratizing access to cutting-edge surgical robotic technologies. After commencing commercial operations in late 2022, the company’s annual revenue has grown from approximately…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII
Forward Industries manages a Solana treasury platform, targeting active participation in the Solana ecosystem in a variety of ways, such as staking and lending.
Currently, Forward Industries’ SOL treasury has liquid SOL holdings of over 7 million, and its validator infrastructure has generated yields that outperforms other peer validators.
The company also recently made an offer and publicized a letter of intent (“LOI”) to acquire the Solana Company.
Forward Industries (NASDAQ: FWDI) is a Solana treasury company that’s backed by some of the most influential investors in the digital asset space. It aims to create long-term shareholder value by actively participating in the Solana ecosystem through various on-chain activities like staking, lending, and decentralized finance (“DeFi”).
It also became the first U.S.-listed company to bring its common stock to the…
NOTE TO INVESTORS: The latest news and updates relating to FWDI are available in the company’s newsroom at https://ibn.fm/FWDI
About MissionIR
MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.
MIR is where breaking news, insightful content and actionable information converge.
Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer
SS Innovations International (NASDAQ: SSII) announced that its subsidiary, the SS International Centre for Robotics Surgery (“SSICRS”), has graduated the inaugural class of its Cardiac Robotic Surgery Training program. The five-day course brought together 33 participants from seven countries and 16 international faculty members for classroom instruction, live surgical demonstrations and hands-on training using the company’s SSi Mantra surgical robotic system.
SS Innovations said SSICRS plans to expand its educational offerings through additional condensed training programs covering multiple surgical specialties, including urology, gynecology, thoracic, colorectal, gastrointestinal and general surgery. The company said the training center combines modern lecture facilities, advanced simulation labs, tele-proctoring and online learning modules to support surgeon education and the broader adoption of robotic-assisted surgery.
SS Innovations International, Inc. develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of surgical robotic procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII
Updating a Mineral Resource Estimate under SEC Regulation S-K 1300 represents an important milestone for companies listed on U.S. exchanges.
Greenland Mines is also continuing to advance the Sarfartoq Neodymium-Praseodymium Rare Earth Magnet Project on several additional fronts.
According to the company, Sarfartoq is distinguished by its concentration of neodymium and praseodymium, commonly referred to as Nd Pr.
As governments and manufacturers race to secure reliable supplies of rare earth elements for electric vehicles, renewable energy technologies and defense systems, projects that can advance toward modern resource estimates and economic studies are drawing increasing attention. Greenland Mines (NASDAQ: GRML), a mineral exploration and development company focused on building a strategic portfolio of critical mineral assets in Greenland, recently announced a significant step forward in the development of its Sarfartoq Neodymium-Praseodymium Rare Earth Magnet Project through an accelerated program to update the project’s mineral resource estimate in accordance with U.S. Securities and Exchange Commission Regulation S-K 1300.
The company has engaged Tetra Tech Canada Inc. and GeoSim Services Inc. to conduct an updated S-K 1300-compliant Mineral Resource Estimate (“MRE”) for the Sarfartoq project in southwest Greenland. Under the agreements, GeoSim will serve as the Qualified Person responsible for the…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to GRML are available in the company’s newsroom at https://ibn.fm/GRML
Greenland Mines (NASDAQ: GRML) announced that Professor Wolfgang Maier and Associate Professor Kristoffer Szilas will join the company’s 2026 field campaign at its Skaergaard precious and critical metals project in southeast Greenland. The company said the appointments strengthen its technical team by bringing additional expertise in layered intrusions, magmatic ore deposits and Greenland geology to support ongoing exploration and development activities.
Greenland Mines said Maier and Szilas will work alongside its in-country leadership and technical consultants as part of a team of more than 40 specialists supporting the 2026 Skaergaard season. The company believes integrating the researchers’ academic expertise with its commercial exploration program will help refine geological models, improve data collection and support future resource evaluation and development planning at the project.
Greenland Mines Ltd. is a Nasdaq-listed company with two operating divisions: (1) Mining, focused on the exploration and development of the Skaergaard Project in southeast Greenland and, subject to closing of the previously announced transaction, the Sarfartoq neodymium-praseodymium (Nd-Pr) rare earths project in southwest Greenland; and (2) Biotech, including Klotho’s KLTO‑202 primary indication for ALS. The Company’s strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to GRML are available in the company’s newsroom at https://ibn.fm/GRML
Wrap Technologies (NASDAQ: WRAP) launched WrapShield, an autonomous defense and public safety platform designed to connect threat detection, AI-assisted decision support and response technologies into a unified operating architecture. The company said the platform is intended to help government agencies integrate existing and future sensors, artificial intelligence capabilities and response technologies across defense, public safety, homeland security, critical infrastructure and border security applications, with its initial focus on counter-unmanned aircraft systems.
Wrap Technologies also announced a strategic investment in Israel-based Frenel Imaging Ltd. along with an exclusive U.S. and NATO license for Frenel’s proprietary TPiCore(R) thermal-polarimetric imaging technology, which will serve as the initial sensing layer for WrapShield. The company said it expects Frenel to be the first of multiple planned investments supporting the platform, which is designed to expand across a range of autonomous security and surveillance markets.
Wrap Technologies, Inc. a global leader in innovative public safety technologies and non-lethal tools, delivering cutting-edge technology with exceptional people to address the complex, modern day challenges facing public safety organizations.
WRAP’s complete public safety portfolio includes the non-lethal BolaWrap(R) 150 device, Wrap Reality(R) immersive training platform, WrapVision(TM) body-worn camera system, WrapTactics(TM) training programs, and next-generation C-UAS solutions like PAN-DA and the 1KC Kinetic Anti-Drone Cassette, all of which supports the Company’s mission to provide safer, scalable, and cost-effective technologies for public safety, defense, and critical infrastructure markets.
With a growing demand for non-lethal tools and techniques to create time, distance and tactical advantage in non-criminal calls, Wrap’s BolaWrap(R) 150 incorporates a multi-sensory distraction of sight and sound as a first response, followed by a non-lethal restraint if further escalation is required. This approach reduces the risk of injury to officers, subjects, and the community.
Wrap’s BolaWrap(R) 150 solution is intended to provide law enforcement with a safer choice for nearly every phase of a critical incident. This innovative, patented device deploys a multi-sensory, cognitive disruption to expand the pre-escalation period and gives officers the advantage and critical time to manage non-compliant subjects before resorting to higher-force options. The BolaWrap(R) 150 is not pain-based compliance. It does not shoot, strike, shock, or incapacitate, instead, it helps officers strategically operate pre-escalation on the force continuum, reducing the risk of injury to both officers and subjects. Used by over 1,000 agencies across the U.S. and in 60 countries, BolaWrap(R) is backed by training certified by the International Association of Directors of Law Enforcement Standards and Training (IADLEST), reinforcing Wrap’s commitment to public safety through cutting-edge technology and expert training.
WrapReality(TM) VR is a fully immersive training simulator to enhance decision-making under stress.
As a comprehensive public safety training platform, it provides first responders with realistic, interactive scenarios that reflect the evolving challenges of modern law enforcement. By offering a growing library of real-world situations, WrapReality(TM) is intended to equip officers with the skills and confidence to navigate high stakes encounters effectively, which we believe leads to safer outcomes for both responders and the communities they serve.
WrapVision is an all-new body-worn camera and evidence management system built for efficiency.
Designed for efficiency, security, and transparency to meet the rigorous demands of modern law enforcement, WrapVision captures, stores, and helps manage digital evidence, ensuring operational security, regulatory compliance, and enhanced video picture quality and field of view.
The WrapVision camera, powered by IONODES, boasts streamlined cloud integration and final North American assembly, with a critical made-in-America roadmap projected for early 2026. This track helps ensure data integrity and helps eliminate critical concerns over unauthorized access or foreign surveillance risks.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to WRAP are available in the company’s newsroom at https://ibn.fm/WRAP
D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave” or the “Company”), the only dual-platform quantum computing company providing both annealing and gate-model systems, software and services, announced it has been selected to receive a $1,566,250 grant from the U.S. National Science Foundation (NSF) through the agency’s National Quantum Virtual Laboratory (NQVL) program. The funding will support D-Wave’s role as a key industry partner in ERASE (Erasure Qubits and Dynamic Circuits for Quantum Advantage) – a project focused on developing foundational technologies for fault-tolerant quantum computing and strengthening U.S. leadership in quantum innovation.
Led by Yale University, the ERASE project brings together researchers from leading academic institutions and industry organizations to advance dual-rail gate-model quantum computing hardware, software, error correction, and applications. D-Wave, through its New-Haven, Connecticut-based subsidiary Quantum Circuits, LLC, will give ERASE researchers access to its superconducting dual-rail gate-model quantum computing resources. The award moves ERASE into the second phase of the NQVL program and underscores the NSF’s continued support for the project’s approach to scalable, fault-tolerant quantum computing.
“NSF’s continued support for the ERASE project highlights the national importance of accelerating progress toward scalable, fault-tolerant quantum computing,” said Dr. Alan Baratz, CEO of D-Wave. “We believe that D-Wave’s dual-rail technology can play a meaningful role in that effort, while building the technical foundation and skilled workforce needed to sustain U.S. leadership in quantum computing.”
D-Wave is a leader in the development and delivery of quantum computing systems, software, and services. It is the world’s first commercial supplier of quantum computers, and the first and only to offer dual-platform quantum computing products and services, spanning both annealing and gate-model quantum computing technologies. D-Wave’s mission is to help customers realize the value of quantum today through enterprise-grade systems available on-premises and via its LeapTM quantum cloud service, which offers 99.9% availability and uptime. More than 100 organizations across commercial, government and research sectors trust D-Wave to address complex computational challenges using quantum computing. Learn more about realizing the value of quantum computing today and how D-Wave is shaping the quantum-driven industrial and societal advancements of tomorrow: https://www.dwavequantum.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by the following words: “believe,” “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “trend,” “estimate,” “predict,” “project,” “potential,” “seem,” “seek,” “future,” “outlook,” “forecast,” “projection,” “continue,” “ongoing,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks discussed under the caption “Item 1A. Risk Factors” in Part I of our most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of our Quarterly Reports on Form 10-Q and in our other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS
The company was selected over nine other finalists, including several established medical technology companies active in robotic surgery.
The award comes as adoption of the SSi Mantra surgical robotic system continues to expand, with more than 11,700 procedures completed globally.
SSi Mantra has received regulatory approvals in 14 countries, supporting the company’s international growth strategy.
More than 2,100 physicians have been trained on the company’s robotic surgery platform, which has been used across more than 170 different procedures.
For investors, the recognition provides an independent industry endorsement as SS Innovations continues to expand its presence in the rapidly growing global surgical robotics market.
SS Innovations International Inc. (NASDAQ: SSII), a developer of innovative surgical robotic technologies, has been named the winner of the Outstanding Company category at the 2026 Surgical Robotics Industry Awards (“SRIA”), receiving recognition from the industry organization for its work in developing and commercializing robotic surgery technology (https://ibn.fm/lDfv9).
The surgical robotics industry has become increasingly competitive as healthcare providers adopt robotic-assisted procedures across multiple specialties and manufacturers seek to expand beyond traditional markets. The award was presented to SS Innovations after the company was selected from a field of…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII
Novartis has agreed to acquire Myricx Bio for $1.1 billion upfront, with up to $400 million in milestone payments, reinforcing strong pharmaceutical demand for next-generation antibody-drug conjugate (“ADC”) technologies.
The latest transaction adds to a growing list of multibillion-dollar ADC and T-cell engager (“TCE”) deals, highlighting continued strategic investment in differentiated antibody platforms.
VERAXA Biotech (NASDAQ: VRXA) operates in one of biotechnology’s most active partnering environments, with pharmaceutical companies continuing to commit billions of dollars to differentiated antibody therapeutics. The latest example came this week as Novartis agreed to acquire Myricx Bio for $1.1 billion upfront, plus up to $400 million in milestone payments, to gain access to the company’s novel N-myristoyltransferase inhibitor (“NMTi”) payload platform and two lead ADC programs. The acquisition reflects continued industry demand for innovative antibody technologies capable of addressing limitations of existing cancer therapies.
The Novartis transaction follows a series of major antibody therapeutics deals, including Jazz Pharmaceuticals’ collaboration with AbCellera, Gilead Sciences’ acquisition of Tubulis and multiple multibillion-dollar ADC licensing agreements. VERAXA is advancing proprietary antibody therapeutics spanning both ADCs and TCEs through its patented BiTAC platform, positioning the company within two therapeutic categories that continue to attract significant pharmaceutical investment, strategic collaborations and acquisition activity.
About VERAXA Biotech AG
At VERAXA, we are building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, we are rapidly advancing our pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.
BiTAC(R) is a registered trademark of VERAXA Biotech GmbH.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA
ParaZero Technologies (NASDAQ: PRZO) announced it has received a purchase order valued at more than $1 million from a U.S.-based customer, marking a significant milestone in the company’s expansion across advanced aerial systems markets. The order follows a dedicated development and integration process and reflects customer confidence in ParaZero’s proprietary technology platform, engineering capabilities and ability to support complex programs from development through deployment. Deliveries are expected to begin in the fourth quarter of 2026 and continue over a 12- to 18-month period.
The company said the order highlights the commercial value of its broader technology portfolio beyond its defense-focused DefendAir family of Counter-UAS products. ParaZero said it remains focused on expanding its customer base and leveraging its core technologies to drive long-term commercial growth across defense, aviation and commercial drone markets.
ParaZero Technologies Ltd. is an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry. Founded in 2014 by aviation professionals and drone industry veterans, ParaZero is a recognized leader in advanced drone technologies, supporting commercial, industrial, and governmental operations worldwide. The company’s product portfolio includes SafeAir, an autonomous parachute recovery system designed for aerial safety and regulatory compliance; DefendAir, a counter-UAS net-launching platform for protection against hostile drones in both battlefield and urban environments; and DropAir, a precision aerial delivery system. ParaZero’s mission is to redefine the boundaries of aerial operations with intelligent, mission-ready systems that enhance safety, scalability, and security.
NOTE TO INVESTORS: The latest news and updates relating to PRZO are available in the company’s newsroom at https://ibn.fm/PRZO
About MissionIR
MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.
MIR is where breaking news, insightful content and actionable information converge.
Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer
Datavault AI (NASDAQ: DVLT) announced that its Dream Bowl I Meme Coin tokens have commenced trading on the Biconomy Exchange under the DREAM1/USDT trading pair. The company said the tokens are intended to provide qualifying shareholders who received prior distributions with potential benefits including liquidity, membership opportunities and participation in future Dream Bowl promotional events, while supporting Datavault AI’s broader digital engagement and tokenization strategy.
The company said eligible shareholders of record as of Nov. 25, 2025, and Jan. 7, 2026, are encouraged to visit DreamBowlCoin.com to learn more about and claim their Dream Bowl tokens. Datavault AI added that the initiative serves as a foundation for expanding its services supporting meme, stable and utility coins for customers while fostering a community centered on statistical achievement and digital commemoration.
Datavault AI(TM) is leading the way in AI-driven data experiences, valuation and monetization of assets in the Web 3.0 environment. The Company’s cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic Sciences and Data Sciences divisions.
Datavault AI’s Acoustic Sciences division features WiSA(R), ADIO(R) and Sumerian(R) patented technologies and industry-first foundational spatial and multichannel wireless, high-definition sound transmission technologies with intellectual property covering audio timing, synchronization and multi-channel interference cancellation. The Data Science division leverages the power of Web 3.0 and high-performance computing to provide solutions for experiential data perception, valuation and secure monetization.
Datavault AI’s platform serves multiple industries, including high-performance computing software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy and more. The Information Data Exchange(R) enables Digital Twins and the licensing of name, image and likeness by securely attaching physical real-world objects to immutable metadata, fostering responsible AI with integrity. The Company’s technology suite is fully customizable and offers AI- and machine-learning-based automation, third-party integration, detailed analytics and data, marketing automation and advertising monitoring.
The Company is headquartered in Philadelphia, PA. Learn more about Datavault AI at https://dvlt.ai.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to DVLT are available in the company’s newsroom at https://ibn.fm/DVLT
VERAXA Biotech (NASDAQ: VRXA) provided a corporate and pipeline update highlighting progress during the first half of 2026, including continued advancement of its proprietary BiTAC(R) platform and growing interest from potential pharmaceutical partners. The company said its pipeline now includes four BiTAC-based T-cell engager programs targeting solid tumors, two bispecific antibody-drug conjugate (“ADC”) programs and two non-BiTAC assets available for partnering. VERAXA said it plans to prioritize investment in its BiTAC portfolio while seeking to monetize selected non-BiTAC programs to help finance future development, with the goal of advancing lead BiTAC-TCE candidate VXA-102 to IND/CTA readiness by early 2028.
Company executives also cited strong industry interest in T-cell engager and ADC technologies, noting that recent partnering discussions at the BIO International Convention and other scientific meetings reinforced confidence in the company’s differentiated BiTAC platform and its potential to secure strategic collaborations. VERAXA said it continues to refine both its pipeline and partnering strategy as it advances its next generation of cancer therapies.
At VERAXA, we are building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, we are rapidly advancing our pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.
BiTAC(R) is a registered trademark of VERAXA Biotech GmbH.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA
The growing focus on critical minerals reflects their importance across nearly every major industrial sector.
Greenland Mines was established with the objective of building a diversified portfolio of critical minerals projects within Greenland.
The company is also pursuing strategic acquisitions and partnerships designed to expand its position within the critical minerals sector.
Critical minerals have become one of the defining strategic resources of the modern economy, underpinning everything from electric vehicles and renewable energy systems to advanced semiconductors and national defense technologies. As governments and industries work to strengthen supply chains and reduce dependence on foreign sources of essential raw materials, Greenland Mines (NASDAQ: GRML) is positioning itself to build a diversified critical minerals platform centered on Greenland’s extensive mineral resources.
The growing focus on critical minerals reflects their importance across nearly every major industrial sector. The U.S. Geological Survey defines critical minerals as nonfuel minerals that are essential to economic or national security and whose supply chains are vulnerable to disruption. These materials, including rare…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to GRML are available in the company’s newsroom at https://ibn.fm/GRML
VERAXA Biotech (NASDAQ: VRXA) announced the initiation of cell line development for its lead BiTAC(R) T-cell engager (“BiTAC-TCE”) program through a collaboration with ATUM, which will apply its Leap-In Transposase(R) technology to generate stable clonal cell lines supporting IND/CTA-enabling activities and future clinical development. The collaboration follows encouraging preclinical data presented at the 2026 American Association for Cancer Research (“AACR”) Annual Meeting and is intended to support CMC development, including early process, analytical and formulation development, as well as the production of material for nonclinical studies.
VERAXA said its BiTAC-TCE platform is designed to improve tumor selectivity by splitting the T-cell engager into two complementary precursors that activate only when both bind separate tumor targets on the same cell. The company believes this conditional “AND”-gated approach could reduce off-tumor toxicity associated with conventional T-cell engagers while maintaining anti-cancer activity, potentially enabling higher dosing and a broader therapeutic window.
At VERAXA, we are building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, we are rapidly advancing our pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.
BiTAC(R) is a registered trademark of VERAXA Biotech GmbH.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA
Greenland Energy (NASDAQ: GLND) is advancing a significant opportunity in Greenland’s Jameson Land Basin, one of the world’s largest remaining underexplored onshore hydrocarbon regions spanning more than 8,400 square kilometers. Under an agreement with 80 Mile, Greenland Energy will fully fund a two-well drilling program planned for the second half of 2026, earning a 70% interest in the project while 80 Mile retains 30%. The basin has attracted decades of industry attention and substantial historical investment due to its potential resource scale. GLND has engaged Halliburton to provide consulting services, logistics planning, and operational support, while additional agreements with Stampede Drilling are expected to enhance drilling capabilities and execution. The company believes these partnerships position it to efficiently evaluate the basin’s potential while leveraging advanced technologies and expertise for Arctic operations.
GLND is an energy exploration company focused on responsibly developing Greenland’s hydrocarbon resources, with an emphasis on the Jameson Land Basin. It aims to advance oil and gas exploration and create a publicly traded platform for Arctic energy development.
Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995 and within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained herein other than statements of present or historical fact, including, without limitation, statements regarding Greenland Energy Company’s (the “Company”) future financial performance, business strategy, operations, financial position, estimated revenues and losses, projected costs, prospects, plans, objectives of management, and expected benefits of the Company’s recent business combination, are forward-looking statements. Forward-looking statements are generally identified by the use of words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “project,”“forecast,” “potential,” “predict,” or the negative of these terms or similar expressions, although not all forward-looking statements contain such identifying words.
These forward-looking statements are based on management’s current expectations, assumptions and beliefs regarding future events and are based on information currently available to the Company. These statements involve a number of risks and uncertainties, many of which are difficult to predict and are beyond the Company’s control, and actual results may differ materially from those expressed or implied by these forward-looking statements. Factors that could cause actual results to differ materially include, among others: (i) Exploration and Geological Risks, including the Company’s status as a development-stage company with no operating history, revenues, or proved reserves; the inherent uncertainty in prospective resource estimates, including that the 13 billion barrel estimate is based on undiscovered accumulations with no certainty of discovery or commercial viability; geological complexity arising from limited seismic data coverage, pervasive igneous intrusions, faulting patterns, and significant Tertiary uplift creating thermal maturity uncertainty; the fact that the basin has never produced a commercial discovery despite decades of study dating back to the 1970s, and a 2008 USGS report stating less than a 10% chance of containing a technically recoverable hydrocarbon accumulation; and high-cost frontier exploration with estimated well costs of $40 million for the first well and $20 million for subsequent wells; (ii) Operational and Environmental Risks, including the challenges of operating in a remote Arctic location with extreme climate, harsh weather, limited daylight, no existing infrastructure, and seasonal access windows for equipment and personnel; drilling hazards such as blowouts, equipment failures, well control events, environmental releases, and accidents inherent in oil and gas operations; reliance on third-party contractors; and climate change scrutiny, as operations in Greenland face increasing opposition from environmental groups and institutional investors due to Arctic drilling concerns; (iii) Regulatory and Political Risks, including the 2021 Greenland drilling moratorium, and while licenses are grandfathered, future regulatory changes could jeopardize operations; geopolitical tensions, including U.S. interest in acquiring Greenland and Greenland’s internal independence movements that could affect operations; permit requirements, as drilling requires Environmental Impact Assessment approval and Field Activities Application approval from Greenlandic authorities; and forfeiture risk, as failure to meet drilling milestones could result in loss of the Company’s right to earn working interests; (iv) Financial and Capital Risks, including significant capital requirements and the need for substantial funding beyond current resources to complete the drilling program; commodity price volatility, as oil, gas, and NGL prices are highly volatile and will heavily influence project viability; a long development timeline during which market conditions may change significantly before potential production, unlike short-cycle shale projects; going concern uncertainty and substantial doubt about the Company’s ability to continue as a going concern without additional financing; and energy transition risk, as global demand for oil may decline due to electric vehicle adoption, renewable energy policies, and changing consumer preferences; and other risks and uncertainties as set forth in the Company’s Prospectus filed with the Securities and Exchange Commission pursuant to Rule 424(b)(4) under the Securities Act on April 29, 2026, in the section titled “Risk Factors”.
Forward-looking statements speak only as of the date they are made. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to GLND are available in the company’s newsroom at https://ibn.fm/GLND
Wrap Technologies (NASDAQ: WRAP) announced that the University of Maryland, Baltimore County has purchased BolaWrap(R) devices and Non-Lethal Response training as part of its initial deployment of non-lethal capabilities for campus safety and security. The company said the deployment is intended to support responsible, measured response by providing officers with an additional non-lethal tool designed to help reduce escalation and create opportunities for safer resolutions.
Wrap Technologies said the UMBC deployment advances its strategy to expand adoption of its public safety portfolio beyond traditional municipal law enforcement into markets including higher education, healthcare, transportation, critical infrastructure and security. The company noted its broader Non-Lethal Response ecosystem also includes Wrap Reality, WrapTactics(TM), WrapVision(TM) and other public safety technologies.
Wrap Technologies, Inc. a global leader in innovative public safety technologies and non-lethal tools, delivering cutting-edge technology with exceptional people to address the complex, modern day challenges facing public safety organizations.
WRAP’s complete public safety portfolio includes the non-lethal BolaWrap(R) 150 device, Wrap Reality(R) immersive training platform, WrapVision(TM) body-worn camera system, WrapTactics(TM) training programs, and next-generation C-UAS solutions like PAN-DA and the 1KC Kinetic Anti-Drone Cassette, all of which supports the Company’s mission to provide safer, scalable, and cost-effective technologies for public safety, defense, and critical infrastructure markets.
With a growing demand for non-lethal tools and techniques to create time, distance and tactical advantage in non-criminal calls, Wrap’s BolaWrap(R) 150 incorporates a multi-sensory distraction of sight and sound as a first response, followed by a non-lethal restraint if further escalation is required. This approach reduces the risk of injury to officers, subjects, and the community.
Wrap’s BolaWrap(R) 150 solution is intended to provide law enforcement with a safer choice for nearly every phase of a critical incident. This innovative, patented device deploys a multi-sensory, cognitive disruption to expand the pre-escalation period and gives officers the advantage and critical time to manage non-compliant subjects before resorting to higher-force options. The BolaWrap(R) 150 is not pain-based compliance. It does not shoot, strike, shock, or incapacitate, instead, it helps officers strategically operate pre-escalation on the force continuum, reducing the risk of injury to both officers and subjects. Used by over 1,000 agencies across the U.S. and in 60 countries, BolaWrap(R) is backed by training certified by the International Association of Directors of Law Enforcement Standards and Training (IADLEST), reinforcing Wrap’s commitment to public safety through cutting-edge technology and expert training.
WrapReality(TM) VR is a fully immersive training simulator to enhance decision-making under stress.
As a comprehensive public safety training platform, it provides first responders with realistic, interactive scenarios that reflect the evolving challenges of modern law enforcement. By offering a growing library of real-world situations, WrapReality(TM) is intended to equip officers with the skills and confidence to navigate high stakes encounters effectively, which we believe leads to safer outcomes for both responders and the communities they serve.
WrapVision is an all-new body-worn camera and evidence management system built for efficiency.
Designed for efficiency, security, and transparency to meet the rigorous demands of modern law enforcement, WrapVision captures, stores, and helps manage digital evidence, ensuring operational security, regulatory compliance, and enhanced video picture quality and field of view.
The WrapVision camera, powered by IONODES, boasts streamlined cloud integration and final North American assembly, with a critical made-in-America roadmap projected for early 2026. This track helps ensure data integrity and helps eliminate critical concerns over unauthorized access or foreign surveillance risks.
NOTE TO INVESTORS: The latest news and updates relating to WRAP are available in the company’s newsroom at https://ibn.fm/WRAP
About TechMediaWire
TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TechMediaWire, text “TECH” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer
Deal activity remains strong in antibody-drug conjugates (ADCs) and T-cell engager (TCE) therapeutics, with pharmaceutical companies continuing to commit substantial capital to preclinical and early-stage innovation.
The Jazz Pharmaceuticals–AbCellera collaboration illustrates how differentiated antibody technologies can command significant financial commitments before entering clinical development.
VERAXA Biotech AG is positioning its technology platform across both ADCs and T-cell engagers, two therapeutic modalities that continue to attract strategic partnerships and acquisitions.
Platform technologies and individual drug candidates both represent potential avenues for future partnering, licensing, and collaboration agreements.
Recent transactions across the sector demonstrate that pharmaceutical companies are actively seeking access to differentiated antibody engineering capabilities rather than waiting for late-stage clinical assets.
Biotechnology investors often focus on clinical milestones, regulatory approvals, and commercial launches. Yet in antibody therapeutics, some of the largest value-creating events occur much earlier. Strategic licensing agreements, research collaborations, and acquisitions, have become important catalysts for companies developing differentiated technology platforms, and have resulted in significant market value shifts. That trend has been particularly evident in antibody-drug conjugates (ADCs) and T-cell engager (TCE) therapeutics. Pharmaceutical companies continue to pursue external innovation as they seek new approaches for treating difficult cancers, creating an environment in which promising technology platforms can attract significant commercial interest well before pivotal clinical trials.
VERAXA Biotech AG (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, occupies a similar part of the innovation ecosystem. The company is developing a diversified oncology pipeline built around next-generation antibody therapeutics, including bispecific ADCs, bispecific T-cell engagers and…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA
Beeline Holdings (NASDAQ: BLNE)announced the completion of its acquisition of artificial intelligence company MagicBlocks, whose technology powers the company’s proprietary AI agent, Bob, and supports automation across its mortgage origination and title operations. The company said full ownership of the technology is expected to accelerate AI-driven automation, reduce production costs and improve the speed and consistency of the borrower experience.
Beeline acquired the remaining interest in MagicBlocks by issuing 209,456 shares of common stock at $2.25 per share, representing approximately $471,276 in consideration. The company said the acquisition will support future product development across mortgage origination, title services, home equity products and digital real estate transactions, while MagicBlocks will continue licensing its platform to other mortgage lenders and financial institutions.
Beeline Holdings, Inc. is a technology-driven mortgage and title platform focused on simplifying home financing through digital innovation, artificial intelligence, and automation. The Company provides residential mortgage lending, title services, and home equity solutions designed to improve efficiency and enhance the borrower experience.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to BLNE are available in the company’s newsroom at https://ibn.fm/BLNE
This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.
Quantum BioPharma executive co-chairman and co-founder Anthony Durkacz appeared as a guest on the BioMedWire Podcast.
Durkacz outlined the company’s strategy for advancing Lucid-MS, the company’s lead drug candidate for multiple sclerosis.
The Quantum BioPharma exec also provided an update on unbuzzd, the company’s innovative, clinically validated alcohol metabolism accelerator designed to help sober people up faster.
Executive thought leadership has become an increasingly important component of corporate communications, particularly in highly specialized industries such as biotechnology. Through podcasts, interviews and other educational forums, company leaders can explain complex technologies, discuss development strategies and provide context that is often difficult to capture in traditional press releases. That approach was recently on display when Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) executive co-chair and co-founder Anthony Durkacz appeared as a guest on the BioMedWire Podcast.
Quantum BioPharma is a biopharmaceutical company focused on developing treatments for neurodegenerative, metabolic and alcohol-misuse disorders, with Lucid-MS and its ownership in commercially product unbuzzd(TM). During the interview, Durkacz outlined the company’s strategy for…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM
Datavault AI (NASDAQ: DVLT) announced a proposed strategic partnership with Patriot Strategic Metals LLC to jointly develop the Strategic Materials Acquisition Platform, an institutional digital infrastructure platform designed to support the financing, tokenization, settlement and lifecycle management of strategic mineral assets. The companies said the platform would combine Patriot Strategic Metals’ strategic metals operations with Datavault AI’s real-world asset tokenization technology, AI-enabled digital infrastructure and blockchain-based settlement capabilities.
The proposed partnership contemplates an initial Phase I platform development program of up to $700 million, subject to financing, definitive agreements, board approvals and regulatory requirements, with approximately $62 million allocated for Datavault AI-related technology integration, licensing and platform development. Datavault AI said the framework is intended to create recurring revenue opportunities through technology licensing, platform services and transaction-based activities, while providing the company with a 25% share of net distributable platform profits unless otherwise agreed for specific transactions or special purpose vehicles.
Datavault AI(TM) is leading the way in AI-driven data experiences, valuation and monetization of assets in the Web 3.0 environment. The Company’s cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic Sciences and Data Sciences divisions.
Datavault AI’s Acoustic Sciences division features WiSA(R), ADIO(R) and Sumerian(R) patented technologies and industry-first foundational spatial and multichannel wireless, high-definition sound transmission technologies with intellectual property covering audio timing, synchronization and multi-channel interference cancellation. The Data Science division leverages the power of Web 3.0 and high-performance computing to provide solutions for experiential data perception, valuation and secure monetization.
Datavault AI’s platform serves multiple industries, including high-performance computing software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy and more. The Information Data Exchange(R) enables Digital Twins and the licensing of name, image and likeness by securely attaching physical real-world objects to immutable metadata, fostering responsible AI with integrity. The Company’s technology suite is fully customizable and offers AI- and machine-learning-based automation, third-party integration, detailed analytics and data, marketing automation and advertising monitoring.
The Company is headquartered in Philadelphia, PA. Learn more about Datavault AI at https://dvlt.ai.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to DVLT are available in the company’s newsroom at https://ibn.fm/DVLT
Cardio Diagnostics Holdings (NASDAQ: CDIO) is a precision cardiovascular medicine company leveraging epigenetics, genetics and artificial intelligence. The company discussed innovative approaches to cardiovascular disease prevention, risk assessment and cost management at multiple national benefits conferences this month. Cardio’s presentations highlight how advanced cardiovascular risk assessment and detection tools can support both improved health outcomes and more effective healthcare cost management.
“The company’s message centers on the idea that earlier identification of cardiovascular risk and disease can potentially enable more targeted interventions and preventive care. Rather than waiting until symptoms develop or major events occur, employers and health plans may benefit from tools that help identify elevated risk or silent disease before they progress,” reads a recent article. “This preventive focus aligns with broader trends in healthcare, where organizations are increasingly emphasizing population health management and proactive risk reduction.”
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (“AI”)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO
Advances in digital health, cloud computing and data analytics are making it possible to move beyond episodic monitoring toward a more comprehensive understanding of cardiovascular health.
HeartBeam’s proprietary HeartBeam System reflects the company’s mission to make cardiac monitoring accessible beyond the walls of a medical facility.
The synthesized 12-lead ECG view provided by the system can help clinicians evaluate rhythm abnormalities and identify rhythm changes that may warrant additional investigation.
Cardiac monitoring is evolving beyond the routine detection of abnormal heart rhythms toward a future where patients and physicians receive timely actionable insights that can guide clinical decisions outside of a healthcare facility. As healthcare increasingly emphasizes earlier intervention and more personalized care, HeartBeam (NASDAQ: BEAT) is developing technologies designed to transform where and how cardiac data are captured, analyzed and shared, including its proprietary, FDA-cleared HeartBeam System, the first portable, cable-free ECG system capable of synthesizing a 12-lead ECG for assessment of arrhythmias.
For decades, cardiac monitoring has relied on the standard 12-lead ECG but its use has been confined to clinical settings, requiring bulky equipment, adhesive electrodes and trained personnel to administer. This means the most clinically meaningful cardiac data is only available in a doctor’s office or hospital and…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT
SS Innovations International (NASDAQ: SSII) announced it has been named the winner of the Outstanding Company category at the 2026 Surgical Robotics Industry Awards, which recognizes a company demonstrating excellence in innovation, commercial success, industry leadership and positive societal impact. The company said the award reflects growing adoption of its SSi Mantra surgical robotic system, which it believes is gaining traction for its advanced technology, user-friendly design, training capabilities and cost efficiency.
As of June 22, 2026, SS Innovations reported that 11,719 multi-specialty procedures had been performed using the SSi Mantra system, including 612 cardiac procedures, 175 telesurgeries and 212 pediatric surgeries. The company also said approximately 2,100 physicians have been trained on the platform, which has been used for more than 170 procedure types and has received regulatory approval in 14 countries.
SS Innovations International, Inc. develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of surgical robotic procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions.
Visit the Company’s website at ssinnovations.com for more information and updates.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
HeartBeam (NASDAQ: BEAT) announced it has completed patient enrollment ahead of schedule in its ALIGN-ACS pilot study evaluating the HeartBeam System for heart attack detection. The study enrolled 120 patients presenting with chest pain at two clinical sites in Belgrade, Serbia, with participants evaluated using both a standard 12-lead ECG and the company’s 3D ECG technology. Data analysis is underway, and HeartBeam plans to present the results at a major cardiology conference later this year.
The company said the study results are expected to support discussions with the FDA on the design of a planned U.S. pivotal trial and a future submission to expand the HeartBeam System’s indication beyond arrhythmia assessment to include heart attack detection. HeartBeam is also evaluating whether completing enrollment ahead of its previously anticipated third-quarter 2026 timeline could support a more accelerated regulatory pathway.
HeartBeam, Inc. is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025(1). The Company holds over 20 issued patents related to technology enablement.
(1)Cleared Indications for Use
The HeartBeam System with 12-Lead ECG synthesis software for arrhythmia assessment received FDA clearance in December 2025. Refer to the Company’s Cleared Indications for Use at https://www.heartbeam.com/indications for details on the intended use of its technology.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT
Cardio Diagnostics has positioned the science of epigenetics at the center of its diagnostic platform.
Looking at an individual person’s epigenetics can provide invaluable insight into the impact of their lifestyle, behavior, and environment.
Epigenetics does more than pinpoint a problem, says CEO; it also provides some level of solution.
When most people think about their risk for heart disease, they think about family history. Did a parent or grandparent have a heart attack? Is heart disease “in their genes”? It’s an understandable assumption, and genetics does play a role in cardiovascular risk. But a growing body of research suggests that DNA sequence alone tells only part of the story, and increasingly, scientists believe it may be the smaller part. The rest of the story is largely written in epigenetics, a field of biology that examines how genes are switched on or off, turned up or down, without any change to the underlying DNA code itself. Cardio Diagnostics Holdings (NASDAQ: CDIO), a medical technology company built around epigenetics-based cardiovascular testing, has positioned this science at the center of its diagnostic platform.
Understanding the basic concept of epigenetics is key. Think of DNA as a massive instruction manual containing every gene a person could ever use. That manual does not change much over a lifetime. What does change is which pages get read, how often and how loudly. Epigenetics is essentially the…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO
Safe Pro Group Inc. has announced that it has delivered against a recent $742,000 U.S. Army order for the company’s Threat Analysis Kits.
The delivered kits include Safe Pro’s edge compute AI powered Navigation Observation & Detection Engine (“NODE”), Black Widow drones from Red Cat Holdings, annual AI model and algorithm software upgrades and operational field analysis support.
Safe Pro was awarded the subcontract and order from a Defense Prime Contractor on behalf of the Army which is seeking field-ready battlefield intelligence capability powered by advanced AI technology.
Safe Pro Group (NASDAQ: SPAI), a mission-driven tech company that develops AI-powered security and defense solutions, recently announced that it has rapidly delivered against a U.S. Army order for Threat Analysis Kits under an award valued at around $742,000 (https://ibn.fm/smCGt).
The Threat Analysis Kit includes Safe Pro’s edge compute AI powered Navigation Observation & Detection Engine (“NODE”) and Black Widow drones from Red Cat Holdings. It also features…
NOTE TO INVESTORS: The latest news and updates relating to SPAI are available in the company’s newsroom at https://ibn.fm/SPAI
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
For decades, cardiovascular risk assessment has centered on a checklist of factors never designed to capture the full biological picture of how heart disease develops.
What makes CHD numbers particularly troubling is that so much of this is preventable.
Cardio Diagnostics has developed clinical tests rooted in epigenetics and genetics fields that examine how genes are expressed and regulated at the molecular level.
Coronary heart disease (“CHD”) remains the leading cause of death in the United States, but the tools doctors have long relied on to detect it early are proving less reliable than many patients assume. Cardio Diagnostics Holdings (NASDAQ: CDIO)reports that approximately 50% of individuals with coronary heart disease do not present with traditional risk factors and conventional risk calculators have an average sensitivity of 39%. In practical terms, that means that many who “look healthy” go on to have CHD and preventable cardiac events such as a heart attack.
For decades, cardiovascular risk assessment has centered on a checklist. Healthcare providers ask about cholesterol levels, blood pressure, smoking history, diabetes status, family history and weight. While these factors matter and are useful pieces of the puzzle, they were never designed to capture the full…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO
This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.
Before any new drug or diagnostic technology can be used widely, it must pass through a series of structured studies designed to answer specific questions.
The milestone highlighted in Quantum BioPharma’s announcement is that patient enrollment in a key pilot study has reached its halfway mark.
Preliminary analyses show a robust signal in acute MS lesions, along with potential sensitivity to gray matter lesions.
Clinical studies are among the most demanding and consequential undertakings in medicine. They require years of planning, careful patient selection, rigorous data collection and ongoing regulatory oversight, all in pursuit of a single goal — generating reliable evidence that a new drug, device or diagnostic tool is both safe and effective. Without this structured process, promising laboratory discoveries would never make the leap to treatments that physicians can confidently prescribe and patients can trust. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on neurodegenerative and metabolic disorders, recently announced in its collaborative imaging study with Massachusetts General Hospital (“MGH”) that the study has reached the halfway point in patient enrollment and early imaging results could support development of its multiple sclerosis drug candidate: Lucid-MS.
Studies of this kind sit at the center of how medicine advances. Before any new drug or diagnostic technology can be used widely, it must pass through a series of structured studies designed to answer specific questions: Does the approach work as intended? Is it safe? And can it reliably detect or…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM
Datavault AI (NASDAQ: DVLT) announced a partnership with 21 In Right Inc., the Clemente family entity that manages the name, image and likeness of Baseball Hall of Famer Roberto Clemente, to apply its data valuation, monetization and digital Twin technologies to preserve and expand Clemente’s legacy. Under the agreement, 21 In Right will use Datavault AI’s platforms to manage and protect Clemente’s NIL rights, create digital Twins and archives, and develop new fan engagement initiatives in collaboration with the Roberto Clemente Foundation and other aligned organizations.
The companies also plan to launch a fan activation in Philadelphia beginning in July featuring demonstrations of Datavault AI’s artificial intelligence tools, Clemente-themed digital collectibles and tributes celebrating the baseball legend’s legacy of excellence and community service.
Datavault AI(TM) is leading the way in AI-driven data experiences, valuation and monetization of assets in the Web 3.0 environment. The Company’s cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic Sciences and Data Sciences divisions.
Datavault AI’s Acoustic Sciences division features WiSA(R), ADIO(R) and Sumerian(R) patented technologies and industry-first foundational spatial and multichannel wireless, high-definition sound transmission technologies with intellectual property covering audio timing, synchronization and multi-channel interference cancellation. The Data Science division leverages the power of Web 3.0 and high-performance computing to provide solutions for experiential data perception, valuation and secure monetization.
Datavault AI’s platform serves multiple industries, including high-performance computing software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy and more. The Information Data Exchange(R) enables Digital Twins and the licensing of name, image and likeness by securely attaching physical real-world objects to immutable metadata, fostering responsible AI with integrity. The Company’s technology suite is fully customizable and offers AI- and machine-learning-based automation, third-party integration, detailed analytics and data, marketing automation and advertising monitoring.
The Company is headquartered in Philadelphia, PA. Learn more about Datavault AI at https://dvlt.ai.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to DVLT are available in the company’s newsroom at https://ibn.fm/DVLT
Zacks Investment Research noted progress in the company’s gamification business and potential growth catalysts despite broader industry challenges.
A key factor was the company’s unique technology, plus improved first-quarter 2026 financial results, including significantly reduced operating losses and positive operating cash flow.
Versus Systems offers a unique technology platform combining interactive gaming, real-world rewards, and advertising experiences designed to increase customer engagement and loyalty.
Versus’ Winfinite and Filter Fan Cam products provide opportunities across digital marketing, sports, entertainment, and live-event environments.
The company’s relationship with ASPIS and the potential extension of its technology licensing agreement may provide future recurring revenue opportunities.
Versus Systems (NASDAQ: VS), a leading provider of gamification and audience engagement technology, has received new attention from the investment community following the initiation of research coverage by Zacks Investment Research, which highlighted the company’s recent operational progress and future growth opportunities (https://nnw.fm/VDBzc).
The research assessment comes as Versus continues to refine its business model and expand its audience engagement technology during a period when companies across marketing, sports, and media…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to VS are available in the company’s newsroom at https://ibn.fm/VSI
HeartBeam (NASDAQ: BEAT) announced a strategic reorganization aimed at accelerating execution, expanding global market reach and improving capital efficiency as it advances commercialization of its cardiac monitoring technology. Under the new structure, Founder and President Branislav Vajdic, Ph.D., and Executive Chairman Rich Ferrari will lead focused implementation teams designed to streamline decision-making, improve accountability and reduce costs. As part of the transition, former CEO Robert Eno will move into a consulting role.
The company said its strategy centers on leveraging its patented 3D ECG platform across multiple healthcare channels while advancing development beyond arrhythmia assessment toward heart attack detection. HeartBeam also plans to expand partnerships with governments, health systems, ECG manufacturers and wearable device companies, building on its December 2025 FDA clearance for its synthesized 12-lead ECG technology for arrhythmia assessment.
HeartBeam, Inc. is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025(1). The Company holds over 20 issued patents related to technology enablement.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT
Greenland Mines (NASDAQ: GRML) announced it has completed a three-day, multidisciplinary planning workshop for its Skaergaard Precious and Critical Metals Project in southeast Greenland, bringing together more than 15 international experts from GTK Mintec, the Geological Survey of Finland, SLR Consulting, WSP Denmark and other technical specialists. The June 22-24 sessions focused on advancing understanding of the orebody and processing pathways, planning 2026 drilling, sampling and environmental programs and establishing a roadmap toward an Initial Assessment (“IA”) or Preliminary Economic Assessment (“PEA”) and future development.
The company said the workshop produced an integrated plan for the 2026 field campaign, a refined metallurgical testing strategy, a framework for incorporating geotechnical and environmental data into mine design and permitting and a long-term development roadmap extending toward a potential exploitation license. Greenland Mines said the workshop builds on its existing collaborations with GTK Mintec, WSP Denmark and SLR Consulting and reflects its strategy of engaging leading international technical experts to advance the Skaergaard project.
Greenland Mines Ltd is a Nasdaq-listed company with two operating divisions: (1) Mining, focused on the exploration and development of the Skaergaard Project in southeast Greenland and, subject to closing of the previously announced transaction, the Sarfartoq neodymium-praseodymium (Nd-Pr) rare earths project in southwest Greenland; and (2) Biotech, including Klotho’s KLTO‑202 primary indication for ALS. The Company’s strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to GRML are available in the company’s newsroom at https://ibn.fm/GRML
VERAXA Biotech has reported new in vitro proof-of-concept data supporting its BiTAC-ADC technology, demonstrating selective activity against cancer cells while sparing healthy cells in early testing.
The company is presenting its BiTAC-ADC and BiTAC-TCE platforms for potential strategic collaborations at the BIO International Convention 2026.
VERAXA’s proprietary BiTAC approach is designed to improve the precision of antibody-based cancer therapies by activating therapeutic effects only in targeted tumor cells.
The company maintains a diversified oncology pipeline of antibody-based formats including antibody-drug conjugates (“ADCs”), T-cell engagers (“TCEs”), and other antibody-based formats.
VERAXA recently began trading on the NASDAQ Capital Market under the ticker symbol VRXA following the completion of its business combination with Voyager Acquisition Corp.
VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has announced new in vitro proof-of-concept data supporting its BiTAC-ADC platform, a technology designed to improve the selectivity of antibody-drug conjugates in cancer treatment. The announcement comes as the company prepares to engage with potential pharmaceutical and biotechnology partners during the BIO International Convention 2026 in San Diego (https://nnw.fm/APy2D).
The newly released data showed that VERAXA’s BiTAC-ADC technology was able to distinguish between breast cancer cells and healthy cells in laboratory studies and demonstrated dose-dependent destruction of three-dimensional tumor cell spheroids. While the platform remains in early development, the results…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA
Massimo Group (NASDAQ: MAMO), a manufacturer and distributor of powersports vehicles and mobility solutions, announced it has terminated its previously proposed acquisition of FST Development Company Limited. The company said that after reviewing its strategic priorities, capital allocation plans and recent development progress, it elected not to proceed with the transaction or the previously contemplated stock-based acquisition structure.
Massimo said recent advancements in its internal development programs and strategic partnerships have strengthened its position in intelligent patrol systems, autonomous patrol vehicles, drone-assisted security technologies and AI-powered monitoring platforms, reducing the need for external acquisitions. To support these initiatives, the company’s controlling shareholder has committed up to $4 million in funding to accelerate product development, testing, pilot deployments and commercialization efforts related to its next-generation intelligent security technology platform.
Massimo Group is a U.S.-based provider of utility-focused powersports vehicles, recreational products, and marine equipment. The Company delivers feature-rich products through a nationwide distribution and service network and is focused on expanding its platform through product innovation, operational execution, and scalable channel development across consumer and commercial markets.
NOTE TO INVESTORS: The latest news and updates relating to MAMO are available in the company’s newsroom at https:/ibn.fm/MAMO
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
Safe Pro Group (NASDAQ: SPAI), has released a demonstration video highlighting its new RoadSight capability, which applies the company’s patented SPOTD (Safe Pro Object Threat Detection) technology to autonomous Unmanned Ground Vehicles (“UGVs”). The video illustrates how Safe Pro’s AI-powered computer vision platform is designed to detect landmines, unexploded ordnance and other explosive threats in real time, complementing the company’s recently announced $1.3 million U.S. Army subcontract to integrate the technology into autonomous UGVs.
Safe Pro Group Inc. is a mission-driven technology company delivering AI-enabled security and defense solutions. Through cutting-edge platforms like SPOTD, Safe Pro provides advanced situational awareness tools for defense, humanitarian, and homeland security applications globally. The Company is a leading provider of artificial intelligence (AI) solutions specializing in drone imagery processing, leveraging commercially available off-the-shelf drones with its proprietary machine learning and computer vision technology to enable rapid identification of explosive threats, providing a safer and more efficient alternative to traditional human-based analysis methods. Built on a cloud-based ecosystem and powered by Amazon Web Services (AWS), Safe Pro Group’s scalable platform targets multiple markets, including commercial, government, law enforcement, and humanitarian sectors where its Safe Pro AI software, Safe-Pro USA protective gear, and Airborne Response drone-based services can work in synergy to deliver safety and operational efficiency.
NOTE TO INVESTORS: The latest news and updates relating to SPAI are available in the company’s newsroom at http://nnw.fm/SPAI
About NetworkNewsWire
NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer
Energy, Oil & Gas Magazine profiles CEO Robert Price as company prepares for October 2026 exploration campaign in East Greenland
Greenland Energy (NASDAQ: GLND) is advancing development of the Jameson Land Basin in East Greenland, an onshore petroleum basin that CEO Robert Price described as one of the world’s last largely undrilled frontier oil regions. In an interview with Energy, Oil & Gas Magazine, Price said the company holds rights to up to a 70% interest in the basin and is leveraging extensive seismic data originally collected by Atlantic Richfield Company (“ARCO”) during the 1970s and 1980s. Modern reprocessing of the historical data has helped refine potential drilling targets within a geological system the company believes shares characteristics with the North Sea.
Price said independent evaluations have suggested upside potential of up to 13 billion barrels across the basin, with the first drill location estimated to contain approximately 2.9 billion barrels. He added that project preparations are underway, including refurbishment and transport of a drilling rig, road construction and logistics planning led by Halliburton, with initial drilling targeted for October 2026.
According to Price, the project could play an important role in future energy security while also contributing to Greenland’s long-term economic development. Drawing comparisons to the impact of resource development in Norway and Denmark, he said stakeholders increasingly view the basin’s potential hydrocarbon resources as a possible catalyst for infrastructure investment, public revenue generation and broader economic growth.
Source: Energy, Oil & Gas Magazine
About Greenland Energy Company
Greenland Energy Company is an energy exploration company focused on responsibly developing Greenland’s hydrocarbon resources, with an emphasis on the Jameson Land Basin. It aims to advance oil and gas exploration and create a publicly traded platform for Arctic energy development.
Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995 and within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained herein other than statements of present or historical fact, including, without limitation, statements regarding Greenland Energy Company’s (the “Company”) future financial performance, business strategy, operations, financial position, estimated revenues and losses, projected costs, prospects, plans, objectives of management, and expected benefits of the Company’s recent business combination, are forward-looking statements. Forward-looking statements are generally identified by the use of words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “project,”“forecast,” “potential,” “predict,” or the negative of these terms or similar expressions, although not all forward-looking statements contain such identifying words.
These forward-looking statements are based on management’s current expectations, assumptions and beliefs regarding future events and are based on information currently available to the Company. These statements involve a number of risks and uncertainties, many of which are difficult to predict and are beyond the Company’s control, and actual results may differ materially from those expressed or implied by these forward-looking statements. Factors that could cause actual results to differ materially include, among others: (i) Exploration and Geological Risks, including the Company’s status as a development-stage company with no operating history, revenues, or proved reserves; the inherent uncertainty in prospective resource estimates, including that the 13 billion barrel estimate is based on undiscovered accumulations with no certainty of discovery or commercial viability; geological complexity arising from limited seismic data coverage, pervasive igneous intrusions, faulting patterns, and significant Tertiary uplift creating thermal maturity uncertainty; the fact that the basin has never produced a commercial discovery despite decades of study dating back to the 1970s, and a 2008 USGS report stating less than a 10% chance of containing a technically recoverable hydrocarbon accumulation; and high-cost frontier exploration with estimated well costs of $40 million for the first well and $20 million for subsequent wells; (ii) Operational and Environmental Risks, including the challenges of operating in a remote Arctic location with extreme climate, harsh weather, limited daylight, no existing infrastructure, and seasonal access windows for equipment and personnel; drilling hazards such as blowouts, equipment failures, well control events, environmental releases, and accidents inherent in oil and gas operations; reliance on third-party contractors; and climate change scrutiny, as operations in Greenland face increasing opposition from environmental groups and institutional investors due to Arctic drilling concerns; (iii) Regulatory and Political Risks, including the 2021 Greenland drilling moratorium, and while licenses are grandfathered, future regulatory changes could jeopardize operations; geopolitical tensions, including U.S. interest in acquiring Greenland and Greenland’s internal independence movements that could affect operations; permit requirements, as drilling requires Environmental Impact Assessment approval and Field Activities Application approval from Greenlandic authorities; and forfeiture risk, as failure to meet drilling milestones could result in loss of the Company’s right to earn working interests; (iv) Financial and Capital Risks, including significant capital requirements and the need for substantial funding beyond current resources to complete the drilling program; commodity price volatility, as oil, gas, and NGL prices are highly volatile and will heavily influence project viability; a long development timeline during which market conditions may change significantly before potential production, unlike short-cycle shale projects; going concern uncertainty and substantial doubt about the Company’s ability to continue as a going concern without additional financing; and energy transition risk, as global demand for oil may decline due to electric vehicle adoption, renewable energy policies, and changing consumer preferences; and other risks and uncertainties as set forth in the Company’s Prospectus filed with the Securities and Exchange Commission pursuant to Rule 424(b)(4) under the Securities Act on April 29, 2026, in the section titled “Risk Factors”.
Forward-looking statements speak only as of the date they are made. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to GLND are available in the company’s newsroom at https://ibn.fm/GLND
Beeline’s AI-enabled underwriting and customer acquisition tools are designed to reduce friction in mortgage approvals, particularly for gig-economy borrowers.
Shares of Beeline Holdings, Inc. are set to join the Russell Microcap Index effective June 29, increasing visibility among institutional investors.
The company’s first-quarter 2026 revenue more than doubled year over year to $2.7 million, while loan originations rose to $85.6 million.
Management is targeting younger real estate investors alongside older homeowners seeking access to home equity without refinancing.
The company continues investing in automation and adjacent software capabilities as it pursues a broader housing finance technology strategy.
Beeline Holdings (NASDAQ: BLNE), a fast-growing digital mortgage platform offering a quicker and easier path to home ownership, was added as a member of the Russell Microcap Index, marking a notable milestone for the digital mortgage company as it attempts to scale its technology-driven lending platform during one of the most challenging housing finance environments in years.
The inclusion, effective June 29 following the annual Russell indexes reconstitution, places Beeline among a group of small-cap companies tracked by institutional investors and index-linked funds. According to FTSE Russell, approximately $12.2 trillion in assets are benchmarked against…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to BLNE are available in the company’s newsroom at https://ibn.fm/BLNE
Cardio Diagnostics Holdings (NASDAQ: CDIO), an AI-powered precision cardiovascular medicine company, announced that Atlas Healthcare Physicians, an independent physician association serving managed care populations across Los Angeles and Orange counties, will provide coverage for the company’s Epi+Gen CHD(TM) and PrecisionCHD(TM) tests for eligible members with prior authorization. The coverage expands access to physician-ordered blood tests designed to assess coronary heart disease risk and support diagnosis and personalized treatment planning.
Cardio Diagnostics said Epi+Gen CHD(TM) evaluates a patient’s three-year risk of a coronary heart disease event, while PrecisionCHD(TM) helps diagnose coronary heart disease and identify its underlying molecular drivers. The company noted that both tests are noninvasive blood-based diagnostics that do not require fasting or radiation exposure, supporting broader adoption of precision cardiovascular medicine across community healthcare networks.
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO
Greenland Mines’ flagship Skaergaard Project hosts an NI 43-101 Mineral Resource estimate containing 11.4 million ounces PdEq in the Indicated category and 14.1 million ounces PdEq in the Inferred category.
The pending acquisition of the Sarfartoq Project would add an advanced rare earth asset with a historical resource estimate, extensive drilling history and exposure to magnet rare earth elements including neodymium and praseodymium.
The company’s relationship with Neo Performance Materials includes an offtake arrangement covering up to 60% of future Sarfartoq production, subject to completion of the acquisition and future project development.
Greenland Mines is pursuing a North Atlantic critical minerals strategy that includes resource development in Greenland and potential downstream processing and logistics initiatives in Iceland.
Greenland Mines’ strategic investment in AnorTech provides exposure to sustainable alumina, high purity alumina and related midstream processing opportunities that complement the company’s broader critical minerals strategy.
Greenland Mines (NASDAQ: GRML) is focused on the exploration and development of mineral assets in Greenland. Through its mining division, the company is advancing the Skaergaard Project in southeast Greenland while also pursuing the acquisition of the Sarfartoq rare earth project in southwest Greenland. Together, these assets provide exposure to precious metals, critical metals and rare earth elements within a jurisdiction that has attracted growing interest as governments and industries seek to diversify strategic mineral supply chains.
The company’s strategy centers on building a North Atlantic critical minerals platform that links resource development in Greenland with downstream processing, logistics infrastructure and industrial markets in Europe and North America. In June 2026, Greenland Mines expanded that strategy through a strategic…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to GRML are available in the company’s newsroom at https://ibn.fm/GRML
VERAXA Biotech (NASDAQ: VRXA) an emerging developer of novel cancer therapies, announced it has expanded its laboratory footprint at its existing research and development site in Heidelberg, Germany, under a previously executed long-term lease agreement. The additional space will support planned growth of the company’s R&D team, installation of new laboratory equipment and completion of infrastructure needed to advance future development activities.
VERAXA said the expansion aligns with efforts to advance its growing portfolio of proprietary and partnered oncology programs from discovery-stage research toward early clinical development. The company’s pipeline is centered on its BiTAC platform, including BiTAC-TCE and BiTAC-ADC candidates, which are designed to enable tumor-restricted activation of cancer therapies through the use of complementary precursor molecules.
At VERAXA, we are building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, we are rapidly advancing our pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA
Safe Pro Group (NASDAQ: SPAI), announced it has received a $1.3 million U.S. Army subcontract from a leading defense prime contractor to integrate its proprietary AI-powered real-time threat detection technology into autonomous Unmanned Ground Vehicles (“UGVs”). The project will incorporate Safe Pro’s computer vision and machine learning pipeline onboard UGVs to detect explosive threats in real time while supporting on-the-move military operations.
The company’s patented SPOTD (Safe Pro Object Threat Detection) technology is trained on one of the world’s largest real-world drone imagery datasets and can identify more than 150 types of explosive threats and objects of interest, including landmines, unexploded ordnance and hostile drones. Safe Pro said its AI models are built on more than 2.8 million drone images and over 50,000 confirmed detections collected across more than 35,000 acres in Ukraine, providing enhanced situational awareness capabilities for military and security applications.
Safe Pro Group Inc. is a mission-driven technology company delivering AI-enabled security and defense solutions. Through cutting-edge platforms like SPOTD, Safe Pro provides advanced situational awareness tools for defense, humanitarian, and homeland security applications globally. The Company is a leading provider of artificial intelligence (AI) solutions specializing in drone imagery processing, leveraging commercially available off-the-shelf drones with its proprietary machine learning and computer vision technology to enable rapid identification of explosive threats, providing a safer and more efficient alternative to traditional human-based analysis methods. Built on a cloud-based ecosystem and powered by Amazon Web Services (AWS), Safe Pro Group’s scalable platform targets multiple markets, including commercial, government, law enforcement, and humanitarian sectors where its Safe Pro AI software, Safe-Pro USA protective gear, and Airborne Response drone-based services can work in synergy to deliver safety and operational efficiency.
NOTE TO INVESTORS: The latest news and updates relating to SPAI are available in the company’s newsroom at http://ibn.fm/SPAI
About MissionIR
MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.
MIR is where breaking news, insightful content and actionable information converge.
Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer
Datavault AI (NASDAQ: DVLT) through its Acoustic Sciences division’s WiSA Technologies, announced that its WiSA E Enterprise wireless audio module has been integrated into Goldhorn’s new Goho LS7 2.0 and 5.1 home audio and karaoke systems. The systems feature 4K Ultra HD projectors and are designed to deliver high-definition stereo and immersive 5.1 surround sound using WiSA’s wireless audio transmission technology, with products now available in China.
The launch expands WiSA’s presence beyond its traditional markets and highlights the scalability of its wireless audio platform. Datavault AI said its WiSA E technology is designed to provide secure, low-latency, high-definition multi-channel audio connectivity and is positioned for use across home entertainment, robotics, holographic systems, drones and other emerging applications requiring synchronized wireless audio distribution and control.
Datavault AI(TM) is leading the way in AI-driven data experiences, valuation and monetization of assets in the Web 3.0 environment. The Company’s cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic Sciences and Data Sciences divisions.
Datavault AI’s Acoustic Sciences division features WiSA(R), ADIO(R) and Sumerian(R) patented technologies and industry-first foundational spatial and multichannel wireless, high-definition sound transmission technologies with intellectual property covering audio timing, synchronization and multi-channel interference cancellation. The Data Science division leverages the power of Web 3.0 and high-performance computing to provide solutions for experiential data perception, valuation and secure monetization.
Datavault AI’s platform serves multiple industries, including high-performance computing software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy and more. The Information Data Exchange(R) enables Digital Twins and the licensing of name, image and likeness by securely attaching physical real-world objects to immutable metadata, fostering responsible AI with integrity. The Company’s technology suite is fully customizable and offers AI- and machine-learning-based automation, third-party integration, detailed analytics and data, marketing automation and advertising monitoring.
The Company is headquartered in Philadelphia, PA. Learn more about Datavault AI at https://dvlt.ai.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to DVLT are available in the company’s newsroom at https://ibn.fm/DVLT
GLND is advancing exploration at the Jameson Project, one of Greenland’s most prospective yet historically underexplored resource regions
The company is focused on unlocking economic opportunities that could support job creation, infrastructure development, and long-term revenue generation
These developments align with a broader vision: empowering Greenland’s path toward greater economic independence through responsible resource development
Greenland Energy (NASDAQ: GLND) is positioning itself at the intersection of one of the Arctic’s most compelling economic opportunities. Through the company’s Jameson Project in East Greenland, it is pursuing resource exploration in an area that has long attracted geological interest but has seen only limited development. As Greenland seeks to improve its economic future and cut down dependence on external financial support, projects like Jameson highlight the critical role responsible resource development can play in building long-term prosperity.
The company’s focus on the Jameson Basin highlights a broader opportunity emerging across Greenland. Despite having significant natural resource potential, much of the country’s resource base is still underexplored relative to other energy-producing regions globally. Advances in exploration…
This communication contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995 and within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained herein other than statements of present or historical fact, including, without limitation, statements regarding Greenland Energy Company’s (the “Company”) future financial performance, business strategy, operations, financial position, estimated revenues and losses, projected costs, prospects, plans, objectives of management, and expected benefits of the Company’s recent business combination, are forward-looking statements. Forward-looking statements are generally identified by the use of words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “project,”“forecast,” “potential,” “predict,” or the negative of these terms or similar expressions, although not all forward-looking statements contain such identifying words.
These forward-looking statements are based on management’s current expectations, assumptions and beliefs regarding future events and are based on information currently available to the Company. These statements involve a number of risks and uncertainties, many of which are difficult to predict and are beyond the Company’s control, and actual results may differ materially from those expressed or implied by these forward-looking statements. Factors that could cause actual results to differ materially include, among others: (i) Exploration and Geological Risks, including the Company’s status as a development-stage company with no operating history, revenues, or proved reserves; the inherent uncertainty in prospective resource estimates, including that the 13 billion barrel estimate is based on undiscovered accumulations with no certainty of discovery or commercial viability; geological complexity arising from limited seismic data coverage, pervasive igneous intrusions, faulting patterns, and significant Tertiary uplift creating thermal maturity uncertainty; the fact that the basin has never produced a commercial discovery despite decades of study dating back to the 1970s, and a 2008 USGS report stating less than a 10% chance of containing a technically recoverable hydrocarbon accumulation; and high-cost frontier exploration with estimated well costs of $40 million for the first well and $20 million for subsequent wells; (ii) Operational and Environmental Risks, including the challenges of operating in a remote Arctic location with extreme climate, harsh weather, limited daylight, no existing infrastructure, and seasonal access windows for equipment and personnel; drilling hazards such as blowouts, equipment failures, well control events, environmental releases, and accidents inherent in oil and gas operations; reliance on third-party contractors; and climate change scrutiny, as operations in Greenland face increasing opposition from environmental groups and institutional investors due to Arctic drilling concerns; (iii) Regulatory and Political Risks, including the 2021 Greenland drilling moratorium, and while licenses are grandfathered, future regulatory changes could jeopardize operations; geopolitical tensions, including U.S. interest in acquiring Greenland and Greenland’s internal independence movements that could affect operations; permit requirements, as drilling requires Environmental Impact Assessment approval and Field Activities Application approval from Greenlandic authorities; and forfeiture risk, as failure to meet drilling milestones could result in loss of the Company’s right to earn working interests; (iv) Financial and Capital Risks, including significant capital requirements and the need for substantial funding beyond current resources to complete the drilling program; commodity price volatility, as oil, gas, and NGL prices are highly volatile and will heavily influence project viability; a long development timeline during which market conditions may change significantly before potential production, unlike short-cycle shale projects; going concern uncertainty and substantial doubt about the Company’s ability to continue as a going concern without additional financing; and energy transition risk, as global demand for oil may decline due to electric vehicle adoption, renewable energy policies, and changing consumer preferences; and other risks and uncertainties as set forth in the Company’s Prospectus filed with the Securities and Exchange Commission pursuant to Rule 424(b)(4) under the Securities Act on April 29, 2026, in the section titled “Risk Factors”.
Forward-looking statements speak only as of the date they are made. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to GLND are available in the company’s newsroom at https://ibn.fm/GLND
For cardiovascular conditions, annual health care costs are forecasted to increase from $393 billion in 2020 to $1.4 trillion by 2050, almost quadrupling in size.
What makes Cardio Diagnostics’ approach distinct, and what gives the company a defensible clinical position, is its ability to detect coronary heart disease earlier and with high sensitivity.
The company’s recent commercial and regulatory milestones give additional shape to the investment thesis.
Heart disease has held the grim distinction of being the leading cause of death in the United States for decades, and despite advances in medicine, the problem is getting worse, not better. According to the American Heart Association (“AHA”), cardiovascular disease accounted for more than 940,000 deaths in the United States in 2022, maintaining its position as the nation’s number one killer. Into that persistent and costly healthcare burden steps Cardio Diagnostics Holdings (NASDAQ: CDIO), a Chicago-based precision cardiovascular medicine company that is applying artificial intelligence, epigenetics and genetics to a problem that traditional diagnostic tools have never fully solved: detecting coronary heart disease, including forms that standard methods routinely miss, from a simple blood draw.
The scale of the problem that Cardio Diagnostics is working to address is difficult to overstate. According to the AHA, cardiovascular disease remains the leading cause of death across men, women, and most racial and ethnic groups in the nation, with one person dying every 34 seconds from the…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO
This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), was featured in a BioMedWire editorial highlighting its development of Lucid-MS, a patented, first-in-class drug candidate designed to directly protect the myelin sheath damaged by multiple sclerosis. Unlike conventional MS treatments that primarily target the immune system, Lucid-MS is being developed as a non-immunomodulatory neuroprotective therapy and is preparing to enter Phase 2 clinical trials following successful Phase 1 safety and tolerability studies.
The editorial notes that Lucid-MS has demonstrated the ability to prevent and reverse myelin degradation in preclinical studies and is supported by more than a decade of scientific research. Quantum BioPharma is also advancing a collaboration with researchers at Massachusetts General Hospital to validate a novel PET imaging technique that may enable direct measurement of myelin integrity in MS patients. The feature additionally highlighted developments across the neurological and immune-mediated disease sectors, including programs from Sanofi (NASDAQ: SNY), Roche Holding AG (OTCQX: RHHBY), Biogen Inc. (NASDAQ: BIIB) and Clene Inc. (NASDAQ: CLNN).
Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented UNBUZZD(TM) and spun out its OTC version to a company, Unbuzzd Wellness Inc. (“Unbuzzd”) (formerly, Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.84% (as of March 31, 2026) of Unbuzzd at www.unbuzzd.com. The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM
Greenland Mines (NASDAQ: GRML) announced it has awarded a diamond drilling contract to Nordisk Fundering A/S for the 2026 field campaign at its 80%-owned Skaergaard precious and critical metals project in southeast Greenland. The planned program will include approximately 7,500 meters of helicopter-supported diamond core drilling aimed at advancing resource categories, collecting additional metallurgical material and supporting geotechnical studies for potential future open-pit development scenarios.
Greenland Mines said the integrated campaign will utilize three helicopter-portable drill rigs and will generate geological, metallurgical and engineering data to support mine planning and broader development studies. The company noted that Nordisk Fundering’s Arctic and geotechnical drilling experience is expected to enhance execution of the program, which will run alongside ongoing metallurgical and processing work being conducted with GTK Mintec to support future economic evaluations of the Skaergaard project.
Greenland Mines Ltd is a Nasdaq-listed company with two operating divisions: (1) Mining, focused on the exploration and development of the Skaergaard Project in southeast Greenland and, subject to closing of the previously announced transaction, the Sarfartoq neodymium-praseodymium (Nd-Pr) rare earths project in southwest Greenland; and (2) Biotech, including Klotho’s KLTO‑202 primary indication for ALS. The Company’s strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to GRML are available in the company’s newsroom at https://ibn.fm/GRML
The seriousness of coronary artery disease continues to intensify as populations age and cardiovascular risk factors become more common.
HeartBeam announced the launch of a pilot study focused on evaluating its on-demand 12-lead ECG patch in detecting coronary artery disease and inadequate blood flow and oxygen supply to tissue, or ischemia.
The study represents a significant step in the development of the HeartBeam patch, which has the potential to disrupt the $2 billion long-term continuous monitor and mobile cardiac telemetry (“MCT”) markets.
Coronary artery disease remains one of the most urgent and widespread health threats worldwide, contributing to millions of deaths each year and often progressing silently until a major cardiac event occurs. As healthcare providers search for faster and more accessible ways to identify high-risk patients earlier, HeartBeam (NASDAQ: BEAT) has launched a new pilot study designed to evaluate its technology — a proprietary on-demand 12-lead ECG patch — in detecting coronary artery disease and inadequate blood flow and oxygen supply to tissue, or ischemia.
“Ischemia detection has not been possible on patch-based ambulatory monitors, and they do not provide clinical-grade insights over an extended period of time,” said HeartBeam CEO Robert Eno. “The HeartBeam patch is designed to change that. A device capable of generating an on-demand…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT
VERAXA Biotech (NASDAQ: VRXA) is highlighting partnering opportunities for its proprietary BiTAC(TM)-ADC and BiTAC-TCE technology platforms ahead of the BIO International Convention, taking place June 22-25 in San Diego. The company recently reported new proof-of-concept data supporting its BiTAC-ADC platform, which is designed to improve cancer treatment precision through tumor-restricted activation of therapeutic agents while minimizing off-target toxicity.
VERAXA said the findings, together with previously presented BiTAC-TCE data unveiled at the American Association for Cancer Research Annual Meeting in April 2026, support the potential of two differentiated cancer therapy platforms that may be applicable across multiple solid tumor indications. Management plans to discuss partnering opportunities for both technologies at the BIO International Convention, scheduled for June 22-25, 2026, in San Diego.
At VERAXA, we are building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, we are rapidly advancing our pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA
